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DEVELOPMENT AND VALIDATION OF UPLC/MS/MS METHODS FOR
QUANTIFICATION OF GANGLIOSIDES IN THE CLINICAL STUDY OF
GANGLIOSIDE GM3 SYNTHASE DEFICIENCY
QIANYANG HUANG

ABSTRACT

Gangliosides are a large subclass of glycosphingolipids that structurally characterized
by the addition of mono- or poly-sialyated carbohydrate moieties onto the ceramide
scaffold. They are presented at significant abundance in the central nervous system of
vertebrates. Their interactions with trans-membrane receptors, especially receptor
tyrosine kinase, are believed to play critical roles in modulating signal transduction
events during cell proliferation, differentiation, migration, and adhesion. Furthermore,
the disruption and dysfunction on their metabolism have been found to be associated
with various neurodegenerative disorders, such as Alzheimer disease, Parkinson’s
disease, and GM3 synthase deficiency. GM3 synthase deficiency (GSD) is a newly
identified neurological disorder that has been prevalently found in the Amish
population in the United States. Although the pathological mechanism remains to be
understood, the condition is severe. It is characterized by infantile onset of severe
irritability, developmental stagnation, profound intellectual disability and intractable
seizures. In order to advance our understanding on the etiology of these
neurodegenerative disorders, especially GSD, analytical assays with sufficient
specificity, sensitivity, and throughput are urgently demanded to practically assist the
v

implementation of relevant clinical studies. In this thesis, three projects have been
conducted separately to benefit the clinical studies from individual aspects. In project
1, owing to the increased complexity of molecular assays in screening and diagnosing
patients affected by GSD associated with increased numbers of identified
nonsense/missense mutations, we have developed and validated a novel
UPLC/MS/MS method with promising sensitivity, specificity, and throughput for four
major ganglioside species, GM2, GM3, GD2, and GD3, in human plasma to facilitate
the diagnosis and screening of GSD. In project 2, in order to obtain more informative
results from GSD patients undergoing clinical trial in relation to the development of
related therapeutic intervention, we have developed and validated a new
UPLC/MS/MS method in human plasma for quantification of monosialogangliosides
in combination with DMTMM&PAEA chemical derivatization for analysis with
superior sensitivity and specificity. In project 3, we have implemented a clinical study
aiming at developing a therapeutic intervention strategy based on oral administration
of commercialized ganglioside-enrich formula to the affected patients.
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CHAPTER Ⅰ

INTRODUCTION

1.1 Gangliosides
Gangliosides are a large subfamily of glycosphingolipids that abundantly present
in the central nervous system of living organisms. Up to date, over 180 ganglioside species
with distinctive structures have been identified in vertebrates [1]. Similar to other
glycosphingolipid species, they possess hydrophilic carbohydrate moieties being added onto
the ceramide backbone except for the presence of sialic acid residues, N-Acetylneuraminic
acid (Neu5Ac), on carbohydrate moieties (Fig.1). This unique combination between the
hydrophobic ceramide portion and hydrophilic carbohydrate moiety with negatively charged
Neu5Ac residues confers them distinctive amphiphilic properties, accounting for their
characteristic behaviors and diverse functionalities in the physiological systems of living
organisms.
Gangliosides are generally classified and nomenclated by the degree of
1

sialylation and the monosaccharide makeup of the carbohydrate moieties. In addition to the
diversity of their carbohydrate moieties, the presence of long alkyl chain fatty acids with
variable chain length and saturation degree in the ceramide portion generates an extra
degree of heterogeneity of their structures [2], implying their physiological versatility in
regulating the central nervous system of living organisms.
Gangliosides have been found to be predominantly localized on the outer
leaflet of plasma membrane of neuronal and glial cells. Generally, they are settled onto the
cell membrane by embedding their hydrophobic ceramide portions inward into the
transmembrane section of the lipid bilayer and protruding their hydrophilic oligosaccharide
moieties outward into the extracellular matrix. This characteristic cell surface configuration
not only allows the ceramide scaffold to act as a functional lipid anchor to clinch them
against the cell membrane with a confined orientation in a very secure manner, but also
enables complete exposure of the oligosaccharide moiety to its surrounding to facilitate
direct interactions with binding ligands from extracelluar matrix in a very accessible
environment [3].
They exert their fundamental functionalities in maintaining integration and
organizing dynamics of lipid bilayer skeleton primarily by serving as ubiquitous
components of characteristic regions, known as glycolipid-enriched microdomains (GEMs)
or lipid rafts, and interacting with other integral membrane components, such as
transmembrane proteins, sphingomyelins, and cholesterols, on the mammalian cell
membrane [4]. They present ubiquitously at significant abundance in the central nervous
system of vertebrates. Mounting evidence has demonstrated that their biosynthesis and
2

metabolism physiologically play pivotal roles for the appropriate development and eventual
maturation of central nervous system in vertebrate during embryogenesis [5]. Moreover,
their cell surface expressions and interactions with transmembrane receptors, especially
receptor tyrosine kinase are believed to be extensively implicated in modulating the signal
transduction during a wide variety of essential cellular events, including cell differentiation
[6-8], proliferation [9-12], migration [13-16], and adhesion [17-20]. However, the depletion,
disruption, and malfunction on their biosynthetic pathway have been illustrated to be
pathologically associated with the pathogenesis of a number of neurodegenerative disorders,
including Parkinson’s disease [21-27], Alzheimer disease [28-34], and GM3 synthase
deficiency [35-37], all of which are neurological syndromes featured by devastating
neurodegenerative impacts with no therapeutic cures available for effective treatment
nowadays. Since the etiologies attributed to those currently incurable neurodegenerative
disorders and the pathological roles played by gangliosides during their pathogenesis have
not been fully understood, considerable numbers of studies related to this area are currently
being undertaken towards the complete elucidation of underlying mechanisms by which
abnormalities on ganglioside biosynthetic and metabolic pathways are etiologically related
to the development of such clinically devastating disorders.

3

Fig.1 Structures of various sphingolipids.
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1.2 Gangliosides’ Nomenclature and Classification
Gangliosides are generally nomenclated by the “two-letter & one-digit” rule
well-defined by Svennerholm [1]. In this nomenclature system, Svennerholm clearly stated
that for a particular ganglioside species GXNy, the first letter “G” denotes the word
“ganglioside”, the second letter “X” serves as a direct indication of the sialylation degree of
the carbohydrate moiety where “M” represents the monosialylation, “D” represents the
disialylation, “T” represents the trisialylation, and “Q” represents the quasialylation, and
the sole digit “N” in this naming system represents different combinations of
monosaccharide units composing the main carbohydrate chain regardless of the number of
sialic acid residues attached. In this regard, the number “4” suggests the oligosaccharide
moiety is solely consisted of β-D-glucose that linked directly to the ceramide portion, the
number “3” illustrates the oligosaccharide moiety is essentially a disaccharide that
composed by β-D-glucose and β-D-galactose linked through 2,5-glycosidic bond, the
number “2” indicates trisaccharide made up by β-D-glucose, β-D-galactose, and
β-D-N-acetylgalactosamine through two sequential 2,5-glycosidic linkages is the
oligosaccharide moiety, and the number “1” describes the oligosaccharide moiety is built
with β-D-glucose, β-D-galactose,

β-D-N-acetylgalactosamine, and β-D-galactose linked

via three consecutive 2,5-glycosidic bonds to obtain a quasaccharide carbohydrate template
with highest degree of structural complexity. Furthermore, with this quasaccharide
carbohydrate template, a number of sialylation sites on the template, including C3 positions
on two β-D-galactoses and C6 position on β-D-N-acetylgalactosamine, have been made
available for the sialic acid residue to be physically bound, which necessitates the
5

application of an additional subscript “y” followed by the digit dedicated for the further
discrimination and classification of GX1 species with sialic acid residues being located
onto disparate monosaccharide units along the carbohydrate platform. Overall, in
consideration of all possible combinations and outcomes on their oligosaccharide moieties,
over 180 ganglioside species with characteristic carbohydrate entities have been identified
in the vertebrates. Detailed information on their nomenclature is shown in Fig.2.

6

Fig.2 Classification and nomenclature of basic gangliosides.
Glucose residue: ①; Galactose residue: ②, ④; N-acetylgalactosamine residue: ③;
N-acetylneuraminic acid residue: ⑤, ⑥, ⑦, ⑧, ⑨, ⑩.
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In addition to their vast structural diversity from the carbohydrate moieties, the
amide-bonded fatty acid chain from the C2 position of ceramide backbone also appears to
possess variable chain length and saturation degree that altering in a very uniform manner.
The amide-bonded fatty acids from the ceramide portion generally start with the length as
short as 14-carbon and gradually lengthens in a 2-carbon increment manner to up to 24
carbons to generate a huge series of long alkyl chain fatty acids with 2-carbon differences
from each other in the overall profile. The amided-bonded long alkyl chain fatty acids are
predominantly unsaturated on 16- and 18-carbon species. According to previous studies on
fatty acid profiling in gangliosides, the individual contribution of a variety of fatty acids
from the ceramide portion to the total abundance of a single ganglioside species could be
varying significantly from one sample specimen to another or even the same sample
specimen at different developmental stages, suggesting differing roles possibly played by
different fatty acid species in different physiological systems [38]. In combination with
their structural diversity on the carbohydrate moiety, this variability on the ceramide
scaffold generates extra degree of structural heterogeneity on gangliosides, conferring them
with great structural complexity as well as physiological versatilities for the mediation of
various cellular events in the central nervous system of living organisms.

1.3 Gangliosides’ Biosynthesis
Gangliosides can be classified into four series, 0-, a-, b-, and c-series,
corresponding to different degrees of sialyation on the lactosylceramide and disparate levels
8

of complexity on their structures. Simple gangliosides, mostly 0- and a-series, are
predominantly expressed in normal human tissues during embryogenesis, whereas the
complex gangliosides from b- and c-series are essentially observed in developing tissues
during later developmental stages. As demonstrated by Fig.3, the de-novo biosynthesis of
gangliosides usually starts off with the addition of a glucose residue onto the ceramide
backbone via the catalysis by ceramide β-glucosyltransferase [39]. Thereafter, the
glucosylceramide (GlcCer) is converted into the synthetic precursor of four series of
gangliosides, lactosylceramide (LacCer), through a single-step reaction catalyzed by GlcCer
β-1, 4-galactosyltransferase (LacCer synthase) [40-41]. Afterwards, specific sialyltransferases
ST3Gal V (GM3 synthase), ST8Sia I (GD3 synthase), and ST8Sia V (GT3 synthase) catalyze
the transfer of Neu5Ac residues onto the LacCer scaffold [42], and synthetic LacCer, GM3,
GD3, and GT3 act as precursors for the downstream biosynthesis along the individual
pathway following the stepwise manner to generate 0-, a-, b-, and c-series gangliosides,
respectively, upon the sequential addition of Gal, GalNAc, and Neu5Ac residues onto the
skeletons from previous synthetic step under the catalysis by the β-1,3-galactosyltransferase
IV [43], β- 1,4-N-acetylgalactosaminyltransferase I [44], and sialyltransferases ST3Gal II
[45-47], ST8Sia V [48], or ST6GalNAc III/V[49-50].
The early biosynthetic stages mainly occur in the cis/median-Golgi, whereas the
later metabolic stages mostly take place in the trans-Golgi and its corresponding organelle
network [51]. The activity of glycosyltransferases is specifically regulated by their locations
on the particular tissue/organ at the transcriptional level [52], leading to their tissue-specific
gene expressions, which could be exemplified with the essential expression of GM2/GD2
9

synthase in embryonic tissue and adult brain, whereas the GM3 synthase is universally
present in all human tissues [53-54]. In addition, post-translational modifications also
regulate the biosynthesis of four series of gangliosides catalyzed by glycosyltransferase via
processes including N-glycosylation, phosphorylation, and dephosphorylation, as protein
kinases A and C are capable of activating the activity of GM2/GD2 synthase while inhibiting
the others [55-57].

10

Fig.3 The stepwise biosynthetic pathways for four ganglioside series [68].
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1.4 Gangliosides’ Interactions with Receptor Tyrosine Kinase (RTK)
Gangliosides are a big family of mono- and poly-sialylated glycosphingolipids
that present abundantly at the outer leaflet of plasma membrane of neuron and gial cells.
They exert the majority of their physiological functionalities by either directly or indirectly
interacting their carbohydrate moieties, which are being placed on an orientation that is
protruding outward into the extracellular matrix, with the extracellular domain of a wide
variety of receptor tyrosine kinases, including including epidermal growth factor receptor
(EGFR) [58], platelet-derived growth factor receptor (PDGFR) [59-62], fibroblast growth
factor receptor (FGFR) [63], nerve growth factor receptor (TrkA) [64-66], and insulin
receptor (IR) [67], as reviewed previously by S. Julien et al. [68]. Receptor tyrosine kinases
(RTK) are proteins that critically involved in the receptor-mediated biological regulation of
numerous essential cellular events, such as cell survival, proliferation, differentiation,
migration, and adhesion. Up-to-date, 58 types of RTKs have been totally identified and
characterized in humans, all of which are sharing high degree of structural homologies that
consisting of three characteristic regions, an extracellular domain containing the
ligand-binding site, a featured transmembrane domain, and a cytoplasmic domain
containing the entire biological machinery of tyrosine kinase. In general, RTKs are
activated upon the binding of the ligands to induce the dimerization of the extracellular
receptor domain, which is usually followed by the subsequent autophosphorylation of the
cytoplasmic domain on the tyrosine residue to activate the downstream signaling cascade.
RTKs are predominantly localized in GEMs along with other integral lipid raft components,
such as gangliosides, choresterols, and sphingomyolins, and associated proteins, such as
12

integrins, tetraspanins, and plexins, to maintain organization and integrity of the GEMs.
Within the GEMs, depending upon the expression pattern of gangliosides, cell type, and
experimental conditions, the signaling of RTKs can be positively/negatively regulated by
gangliosides through either direct or indirect interactions as summarized in Fig.4 [69-70].
Furthermore, alterations on the expression patterns and levels of gangliosides are
implicated in regulating the activity of RTKs by reorganizing/excluding RTKs from GEMs
to affect their relative abundance to be presented in GEMs through modifications on
molecular composition and 3-dimensional structure of GEMs [71-73]. Finally, the presence
of gangliosides was also demonstrated to be one of the determining factors for the crosstalk
between RTK subunits and other lipid raft associated proteins to be physiologically
undertaken and appropriately regulated.
Based on previous studies, three different mechanisms have been identified
and described to be critically involved in the regulation of RTKs by gangliosides: the
regulation on the degree of ligand binding to the targeted receptors by gangliosides as in
the case of fibroblast growth factor (FGF)/GM1 interaction where the binding of FGF to
fibroblast growth factor receptor (FGFR) is down-regulated by increased level of GM1, the
regulation of receptor dimerization as in the case of epidermal growth factor receptor
(EGFR)/GM3 interaction where the usual dimerization of EGFR upon the binding of
epidermal growth factor (EGF) is inhibited in the presence of GM3 to prevent the tyrosine
residue from being subsequently phosphorelated, and the regulation of RTKs activity by
affecting their localization in GEMs as in the case of IR/GM3 where the degree of insulin
receptor (IR) delocalization in GEMs is up-regulated to reduce the ligand/receptor
13

interaction by decreasing binding sites from IR available for the binding of insulin in the
presence of GM3 in GEMs [69, 74]. Generally, these three mechanisms predominantly
account for the majority of known interactions and pathways through which the signaling
and activity of RTKs could be potentially regulated by gangliosides.

14

Fig.4 Biological regulations on different RTKs by gangliosides [68].
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1.5 Ganglioside GM3 Synthase Deficiency (GSD)
GM3 synthase, or so-called lactosylceramide α-2, 3-sialyltransferase, is a
ubiquitously expressed protein that is predominantly localized in the Golgi apparatus and
presented at particularly high abundance in the central nervous system of vertebrates. This
protein is responsible for catalyzing the enzymatic transferring of Neu5Ac onto the
lactosylceramide backbone via α-2, 3-glycosidic linkage to generate GM3 ganglioside,
which is the first step in the de-novo biosynthesis of complex ganglioside species a- and
b-series as shown in Fig.5. This enzyme is encoded by ST3Gal5/SIAT9 gene which is
located on chromosome 2p11.2 and composed of 14 exons that encoding a 419 amino acid
protein in human with minor variance in the amino acid sequence among different species.
The full-length GM3 synthase protein is found to be containing three characteristic regions,
a single short transmembrane region and two sialyl motifs, long and short, each of which
possesses a highly-conserved cysteine residue that has been demonstrated by previous
studies to be essential for the enzyme to be able to exert its normal catalytic activity for the
biosynthesis of GM3 ganglioside [75].
Recently, a single-nucleotide polymorphism has been identified and described
in a large Old Order Amish pedigree, which is believed to be associated with an autosomal
recessive mutation occurred on the GM3 synthase to affect its normal catalytic activity,
leading to the complete loss-of-function on the enzymatic activity of GM3 synthase and
thus premature biosynthetic termination of GM3 ganglioside in the individual affected by
homozygous mutation. Based on previous studies, this autosomal nonsense mutation has
been found to be geographically located at the exon 8 of ST3Gal5/SIAT9 gene right
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between the long and short sialyl motifs and genetically associated with a single nucleotide
substitution on original C base in unaffected individuals to T base in homozygous mutants
at position 694 of the genome, which predictably switches the original “CGA” codon
representing the translation of amino acid arginine to mutated “TGA” codon representing
the immediate termination of the translation machinery, leading to the untranslated short
sialyl motif on the mutated protein with truncated primary sequence, the complete loss of
enzymatic capability of catalytically converting lactosylceramide to GM3 ganglioside on
the functional protein, and thus the premature biosynthetic termination of GM3 ganglioside
in individuals affected by this homozygous autosomal recessive mutation.
Unfortunately, as shown by the biosynthetic pathway of gangliosides in Fig.Ⅴ,
since the biosynthesis of GM3 ganglioside essentially serves as the initial step for the
stepwise de-novo biosynthesis of more complex a- and b-ganglioside series from
lactosylceramide, the enzymatic dysfunction on GM3 synthase not only terminates the
biosynthesis of GM3 ganglioside itself, but also physiologically depletes the formation of
more complex a- and b-ganglioside series in the biological system of homozygous mutants,
which has been found to be clinically associated with devastating manifestations as the
phenotypes accounted for this unique mutation. The syndrome resulted from this autosomal
recessive mutation has been illustrated by previous studies to be an infantile-onset
symptomatic epilepsy that characterized by the development of cortical blindness,
choreoathetosis, flaccid weakness, seizures, profound developmental stagnation, and
become completely caregiver dependent as its primary clinical outcomes [35, 76-77].
However, although the evidence on casual role played by altered ganglioside
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levels in the etiology of this severe infantile-onset neurological disorder and implicate
genes involved in ganglioside biosynthesis as candidates for causing other related human
diseases has been well documented, the actual cause on whether the epileptic phenotype is
attributable to either the physiological deficiency of GM3 and its downstream derivatives
or the accumulation of ganglioside biosynthetic precursors caused by lack of flux through
the a- and b-series ganglioside pathways remains to be further elucidated and understood
by future studies.
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Fig.5 Ganglioside biosynthesis and GM3 synthase deficiency.
The darkened box indicates all gangliosides that cannot be synthesized in the absence of
GM3 synthase. CGT: Ceramide glucosyl transferase; LCS: LacCer synthase; GM3S:
GM3 synthase; GD3S: GD3 synthase; GalNAcT: GalNAc transferase. The major
glycosphingolipid (GSL) are color coded and the major ganglio- (blue; a- and b-series,
brown; o-series) and alternative globo- (pink) and neolacto- (green) series GSLs derived
from the immediate precursor, LacCer, are delineated. The a- and b-ganglio series (blue)
are absent in the plasma of the affected children [35].
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1.6 Hypothesis
Due to the lack of effective cure for GSD, the individuals affected by this
homozygous mutation seem to be continuously suffering from this condition even after our
current understanding on the disease etiology has been well described and established.
However, we have always believed that this neurological condition is practically treatable
from the time it was identified. In fact, we have noticed a very distinguished phenomenon
that the affected kids appear to be fairly normal for approximately eight weeks after their
birth, which hints us to speculate that the affected children might have acquired sufficient
amount of gangliosides from maternal circulation before their birth to make the symptoms
remain undeveloped during the early age after birth and then gradually develop related
symptoms after the endogenous gangliosides have eventually been depleted. Based on this
rationale, it becomes rather reasonable that if we can replace the deficient gangliosides
caused by this genetic defect in those affected kids with continuous supplement of
exogenous gangliosides from handful sources, we might be able to correct their
pathological stigmas and partially or even completely restore the normal ganglioside
biosynthetic pathway, which might eventually lead to a potential cure.
So, in the past few years, extensive searching has been performing worldwide
for the available sources of supplemental gangliosides that are compatible with our
intended clinical trial. Initially, the animal tissues with relatively more abundant
ganglioside content appeared to be the most enriched and accessible natural source we
could find for the study. Therefore, three affected newborns were continuously given with a
pork brain formula once they were diagnosed with DNA mutation analysis soon after birth.
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This formula essentially provided approximately 10 mg GM3 per day, with incremental
amounts given along with their weight gain. Incredibly, all infants being treated showed no
early signs or symptoms of the disease except hypotonia when they were fed on the pork
brain formula, although the effects seemed to be not comparably dramatic when the similar
therapy was conducted on the older children. Unfortunately, all young children involved in
the study started to develop an allergic reaction against the pork brain formula by 9 months
of age, thus this pork brain formula-based therapy had to be discontinued on those affected
kids from that point, and our searching for new ganglioside-enriched supplemental
products continued to move on.
In the course of searching for new treatments, we identified a
highly-concentrated and formulated dairy ganglioside product called G500 manufactured
by Fonterra in New Zealand. This product primarily contains GM3 and GD3, and has been
used as a nutritional supplement in normal infants in the previous study [78]. By
developing a collaborative partnership with this company, the project needs of acquiring
large-scale nutritional ganglioside-enriched supplement product have become practical and
feasible for the subsequent clinical studies.
Considering the promising preliminary results we have observed in the
younger children fed with pig brain formula, to begin with, we hypothesize that the orally
administered gangliosides may be adequately absorbed and taken up into the circulation of
affected patients, and utilized by their metabolic pathway. In addition, we further
hypothesize that the gangliosides can be delivered across the blood-brain barrier, used by
the brain of affected patients, and compensate for metabolically deficient gangliosides in
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their physiological system. Finally, we hypothesize that if the absorption and utilization of
administered GM3 is a reversible pathological process, some of the manifestations and
symptoms associated with this neurological disorder might get partially or even completely
relieved by introducing adequate amounts of GM3 into their body, particularly into the
CNS, which may potentially lead to a normal life in these children when the exogenous
GM3 in adequate quantity was given before they started to develop the related symptoms.
From the perspective of evaluating the effectiveness of new therapy as well as
the recovery stage of studied patients, it will be very essential to periodically collect bodily
fluid samples from the physiological circulations of treated patients and accordingly
implement the quantitative analysis on those collected samples to determine the absolute
levels of gangliosides presented in their bodily fluids as the most important criteria for
assessing bioavailability and metabolism of administered exogenous gangliosides from
G500. Unfortunately, the established quantitative assays with sufficient detection
sensitivity and specificity to meet the stringent requirements of the clinical study have not
yet been reported on the literature up to date. As a result, the need of establishing a
sensitive and reliable quantitative assay dedicated for this study has been urgently
demanded.
In addition, based on our current understanding on the disease etiology, this
disease is essentially an inherited metabolic disorder associated with compromised GM3
biosynthetic capability and premature endogenous ganglioside depletion, implying the
pattern of disease progression is very likely to be critically age-dependent and the
timeframe is one of the most important determining factors pertaining to the success of the
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therapy. As a result, younger patient might be subjected to shorter exposure of
physiological damages associated with premature endogenous ganglioside depletion and
thus standing a better chance of getting cure and recovered by the proposed therapy,
enforcing the disease to be ambiguously diagnosed as early as birth. Unfortunately, despite
the characterization of disease, the prevalence of the disease remains unknown, and we
believe most of the affected individuals are, with no doubt, under-diagnosed due to the
complex and time-consuming nature of the DNA mutation analysis. Therefore, a rapid
quantative method with promising sensitivity, specificity, and ruggedness dedicated for the
early-on newborn screening and clinical diagnosis of GSD is also in urgent need.
Hence, the projects aiming at developing quantitative method in human plasma
for rapid clinical screening and on-birth diagnosis of GSD by UPLC/MS/MS, developing
highly-sensitive method for quantification of monosialogangliosides in biological fluids
UPLC/MS/MS, and elucidating the potential efficacy and efficiency of the G500 therapy
with intended clinical studies by a combination of different methodologies have been
described in detail in the following chapters.
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CHAPTER Ⅱ

DEVELOPMENT AND VALIDATION OF UPLC/MS/MS METHOD IN HUMAN
PLASMA FOR RAPID SCREENING AND DIAGNOSIS OF GSD

2.1 Introduction to Current Diagnostic Method of GSD and High Performance Liquid
Chromatography Interfaced to Mass Spectrometry (LC-MS)
Currently, the molecular-based DNA mutation analysis has been the only
commercially available method for diagnosing individuals affected by this unique nonsense
mutation associated with the pathogenesis of GSD. Since the time when the etiology and
pathology of GSD were described by Simpson et al [1] in 2004, with the assistance of the
molecular-based DNA mutation analysis, more than 50 patients have been diagnosed to be
affected by GSD from the Amish population around the US. Recently, cases with positive
diagnosis of GSD affection have also been reported in other populations, including African
American and European[2,3], suggesting that the actual prevalence of GSD in the US as well
as worldwide might be much broader than we speculated and have been highly
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underestimated. As a result, the practical need of implementing a screening and diagnostic
study has been extremely urgent for the precise determination of actual prevalence of GSD.
However, based on the GSD cases reported in African American as well as European
population, it has been discovered that the occurrence of those cases is etiologically
associated with alternative homozygous nonsense mutation 862C>T located at exon6 of
ST3Gal5/SIAT9 in European, whereas another homozygous missense mutation 994G>A
located at exon7 was identified in cases from African American, both of which are known
to be capable of causing the major enzymatic dysfunction of GM3 synthase. With the
increased number of mutations that determined to be associated with the pathogenesis of
GSD, the workflow of molecular-based DNA mutation analysis could be potentially
complicated, which might significantly reduce the analytical throughput to complete the
screening and diagnosis of GSD, making this molecular diagnostic technique targeting
DNA mutation being no longer suitable for implementing this study in a very efficient and
dynamic fashion. So, the development of alternative methods with desired sensitivity,
specificity, and throughput has been urgently demanded by this particular study.
HPLC is a chromatographic separation technique where the sample is forced
by a liquid at high pressure (the mobile phase) through a column that is packed with a
stationary phase generally composed of irregularly or spherically shaped particles chosen
or derivatized to accomplish particular types of separations. HPLC methods are historically
divided into two different categories based on stationary phases and the corresponding
required polarity of the mobile phase. Use of octadecylsilyl (C18) and related
organic-modified particles as stationary phase with pure or pH-adjusted water-organic
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mixtures such as water-acetonitrile and water-methanol are used in techniques termed
reversed phase liquid chromatography (RP-LC). The materials such as silica gel as
stationary phase with neat or mixed organic mixtures are used in techniques termed normal
phase liquid chromatography (NP-LC). RP-LC is most popularly used technique to
introduce samples prior to MS detection in LC-MS instrumentation.
Mass spectrometry (MS) is an analytical technique that measures the
mass-to-charge ratio of charged particles. It is generally used for measuring masses of
particles, determining the elemental composition of a sample, and elucidating the chemical
structures of molecules. In general, MS instrumentations consist of three modules, a
ionization source, a mass analyzer, and a detector. In this setup, the ionization source
enables the direct transformation of molecules in gaseous/liquid phase into gaseous ions
that being detectable by the mass analyzer. Within the mass analyzer, the gaseous ions
would be separated and analyzed based on their mass-to-charge ratios through a wide
variety of mechanisms, such as quadrupole mass filter and magnetic mass sector, to allow
subsequent detection by the detector. In the course of detection, the detector magnifies the
ion counts into the electronic flow and generates a data set correlates the mass-to-charge
ratio to the intensity of electronic flow, which is known as mass spectrum.
Recently, the emerging and advance of electrospray ionization technique,
which rapidly desolvates and ionizes molecules directed from liquid flow into gaseous
phase with minimal degree of induced in-source decay, has given rise to the combination of
HPLC to MS that physically incorporates the separation capabilities of HPLC into the mass
analysis capabilities of MS to achieve the on-line separation and simultaneous detection of
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different molecules in very complex sample mixture. With the advent of LC-MS, the
excellent quantitative perform featured by promising sensitivity and resolution for the
determination of gangliosides has been enabled to achieve analysis with small sample
requirement and high throughput. Gu et al. established a method for simultaneous
quantification of GM1 and GM2 gangliosides in human cerebrospinal fluid using reverse
phase LC/MS [4]. Sorensen et al. reported a liquid chromatographic approach interfaced
with tandem mass spectrometry for the quantification of gangliosides GD3 and GM3 in
bovine milk and infant formula [5].
However, LC/MS/MS methods established for plasma samples, one of the
handiest biological samples in terms of collection, with desirable speed of analysis for the
study has not been reported by previous studies. As a result, in the present work, we have
developed and validated a UPLC/MS/MS method for the measurement of four common
ganglioside species including GM2, GM3, GD2, and GD3 in human plasma to facilitate the
early-on newborn screening and clinical diagnosis of GSD. This assay employs a simple
protein precipitation strategy for sample extraction, UPLC for chromatographic separation,
and tandem mass spectrometry in the MRM mode for detection to achieve high sensitivity
and specificity for rapid analysis. Moreover, due to the limitation of availability of
analyte-free plasma, a three-level standard addition calibration rather than seven-level
conventional calibration was utilized to establish the matrix-matched analytical platform as
required by the FDA for the quantification of small molecules in biological fluids. This
method has been successfully applied to measurements of these four common ganglioside
species in plasma samples from normal adults. Considering the sensitivity, specificity, and
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quickness of this method, we think it is very suitable for the rapid clinical screening and
diagnosis of GSD as well as other ganglioside-related disorders during the early stage of
the disease development.

2.2 Materials and Methods

2.2.1 Materials
Ganglioside standards GM3 and GD3 were purchased from Avantilipids
(Alabaster, AL). GM2 and GD2 ganglioside standards were obtained from EMD Chemicals
(Billerica, MA) and Enzo Life Sciences (Farmingdale, NY), respectively. The internal
standard (IS) N-omega-CD3-Octadecanoyl monosialoganglioside GM3 (GM3-D3) was
purchased from Matreya LLC (Pleasant Gap, PA). HPLC grade methanol and isopropanol
were obtained from EMD Milipore (Billerica, MA). Deionized water was prepared through
the Barnstead Nano-PURE Water Purification System (Asheville, NC). Ammonium acetate
was from VWR (Bridgeport, NJ).

2.2.2 Human Plasma
The study was approved by the DDC Clinic Institutional Review Board, and
written informed consent was obtained from their legal guardians. Clinical information was
collected when the patients received medical services at DDC Clinic. Human plasma samples
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were stored at -20℃before analysis.

2.2.3 Stock and Working Solutions
Stock solutions of GM2, GM3, GD2, GD3, and IS 2D3-GM3 were prepared by
dissolving the original materials individually into 80% MeOH to obtain a concentration of
0.25 mg/ml for each, and were stored at -20 ℃ before use. Three working solutions were
prepared in 80% MeOH from the stock solutions to obtain ganglioside concentrations as
following: 3, 13.6, 0.125, 2 µg/ml (WS-QC); 4.5, 20.4, 0.125, 3 µg/ml (WS-1), and 18,
81.6, 0.5, 12 µg/ml (WS-2) for GM2, GM3, GD2, GD3, respectively. The IS stock solution
also served as a working solution, named as WS-IS. These working solutions were used for
preparation of spiked plasma samples as below.

2.2.4 Plasma Sample Preparation
For method validation, known-concentration samples were prepared by spiking
ganglioside standards into the analyte-free plasma from patients with GM3 Synthase
Deficiency. In brief, 30 µL of analyte-free plasma was transferred into each of three 0.6-mL
centrifuge vials (a, b, and c) followed by individual addition of 10 µL WS-QC to obtain the
plasma concentrations of 1.00, 4.53, 0.04, and 0.67 g/ml for GM2, GM3, GD2, and GD3,
respectively. Thereafter, 10 µL of 80% methanol, WS-1, and WS-2 were spiked into the
vials a, b, and c, respectively. Afterwards, 10 µL of WS-IS was spiked into each of the three
samples, and this set of samples were named as spiked analyte-free plasma (SAP), Standard
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Addition 1 (SA-1), and Standard Addition 2 (SA-2), respectively.
For measurement of the gangliosides in unknown plasma samples from normal
human subjects, similar procedure as described above was followed except that WS-QC
was not added. The three samples in each set were named as unknown plasma sample
(UPS), SA-1 and SA-2, respectively. All the plasma samples were extracted as described
below prior to LC/MS/MS analysis.

2.2.5 Sample Extraction
Following the plasma sample preparation, 240 µL of methanol was added into
each of them followed by vigorous vortexing. Then, the spiked samples were subjected to
centrifugation at 14,000 G for 15 min at 4 ℃ for protein precipitation. The supernatants
were transferred into auto-sampler vials with micro-inserts for LC/MS analysis.
2.2.6 LC/MS Instrumentation
The UPLC system was composed of a DGU-20A3R degasser, two LC-30AD
pumps, a SIL-30AC autosampler, a CTO-10A column oven and a CBM-20A system
controller from Shimadzu (Columbia, MD). The UPLC system was interfaced to a Qtrap
5500 mass spectrometer equipped with an electrospray ionization source and a built-in
Valco switch valve from AB SCIEX (Framingham, MA). The Multiple Reaction
Monitoring (MRM) mode was utilized for quantitation. Data acquisition and
chromatographic peak integration were conducted using Analysis 1.6.1 software package
from AB SCIEX.
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2.2.7 LC/MS/MS Procedure
After extraction, 30 µl of each sample was injected onto a Kinetex-C18 UPLC
column (1.7 µm, 50 mm × 2.1 mm; Phenomenex, Torrance, CA) guarded with a C18
Security Cartridge. The mobile phase was a mixture of 2% MeOH plus 5 mM ammonium
acetate (A) and MeOH-Isopropanol (1:1) plus 5 mM ammonium acetate (B) using the
gradient program shown in Table 1. The LC flow at 0.3 mL/min was introduced to the
waste within the first 2 minutes, and then switched to the mass spectrometer between 2.1
and 9 minutes while all the monitored ganglioside components were gradually eluted out.
Afterwards, the LC flow at 0.6 mL/min was directed to the waste again, during which the
column was cleaned up and re-equilibrated for next run. The column temperature was
constantly controlled at 35 ℃ during the analysis.

42

Table 1 Optimized UPLC conditions for the separation of gangliosides
Time
Flow rate
Minute
B%
(ml/min)
Stage
0
30
1
30
2
70
Elution
0.3
2.01
70
9
95
9.01
95
Cleanup
15.5
95
0.6
15.51
30
19.5
30
Equilibration
19.51
30
0.3
20.0
30
A: 2% MeOH + 5 mM Ammonium Acetate
B: MeOH - Isopropanol (1:1) + 5 mM Ammonium Acetate
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Valco Switch Valve
To waste
To MS

To waste

2.2.8 Calibration Curve
Quantitation of the gangliosides in the spiked analyte-free plasma (SAP) and
unknown plasma samples (UPS) was implemented using standard addition calibration
based on three levels, including one to-be-measured sample with nil addition and two
standard addition calibrators (SA-1 and SA-2). For each measured ganglioside specimen,
the total peak area (TPA) was obtained by summing the individual peak area from every
MRM transition channel in the corresponding sample from a single injection.
The three-level calibration curve for each ganglioside sample was then
established by plotting its normalized TPA by the internal standard as y-axis versus the
plasma concentration of standard addition as x-axis. The linear regression with a weighting
factor of 1/y2 was employed. The calculation of each ganglioside plasma concentration in a
sample was conducted using the corresponding equation obtained from the regression line
as its intercept with x-axis through extrapolation. Exemplified standard addition calibration
curves for each of the four measured gangliosides from the measurement of healthy
individuals were shown in Fig.6.
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Fig.6 Exemplified calibration curves for GM2 (A), GM3 (B), GD2 (C), and GD3 (D)
from the measurement of a healthy subject.
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2.3 Results and Discussions

2.3.1 Product Ion Mass Spectra
The representative product ion mass spectra of D18:1-20:0 ganglioside
components for the four ganglioside species from added standards were shown in Fig.7.
Apparently, fragmentation pattern relevance can be observed within GM series and GD
series, including the common product ions m/z = 274 and 292 for GM series, and m/z =
290 and 581 for GD series. Owing to their relatively greater molecular masses, the
singly-charged ions of gangliosides are beyond the detection ranges of our mass
spectrometer and many other commercially available triple quadruple instruments.
Therefore, the selection of doubly-charged precursor ions and their appropriate daughter
ions as MRM transition channels has been necessitated for quantitation in this assay.
For GD series, two proton-donating carboxyl groups are attached to their sialic
acid moieties in the carbohydrate portion, the generation of doubly-charged ions had been
observed to be more favorable in the negative than that in a positive ionization mode. For
GM series that contain only one proton-donating carboxyl group, the signal responses from
doubly-charged precursor ions were practically undetectable in a negative ionization mode
under various conditions we studied during the method development. Since the positive
mode was found to be more effective in yielding doubly-charged precursor ions from GM2
and GM3, positive ionization has been selected for determining GM series.
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Fig.7 The product ion (MS/MS) spectra for D18:1-20:0 components of GM2 (A), GM3
(B), GD2 (C), and GD3 (D).
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After evaluating different pairs of precursor → product ions for quantitation, it
was revealed that the following MRM transitions provided the optimal sensitivity and
selectivity: [GM2+2H+]2+ → 204, [GM3+2H+]2+ → 274, [GD2-2H+]2- → 290, and
[GD3-2H+]2- → 290. The fragmentation mechanisms from the precursor to the daughter
ions have been interpreted and elaborated in Fig.8.

2.3.2 Selection of MRM Transitions
As known, each ganglioside species include multiple components that share
the same oligosaccharide moiety but differ in fatty acid chain length within their ceramide
portion. For accurate quantitation, all the major ganglioside components from each
ganglioside species with appreciable abundance in the plasma and commercial standards
need to be detected in the analysis. Therefore, we first carried out a screening study on
predominant ganglioside components of individual ganglioside species in both normal
human plasma and commercial standards using the predicted MRM channels through
LC/MS/MS analysis. The selected MRM transitions corresponding to all the significant
ganglioside components observed by such analysis for the quantitation of the four
ganglioside species are listed in Table 2. In addition to the quantitation MRM channels,
quality assurance MRM channels with transitions from their precursor ions to m/z 274, 292,
290, and 290 were also employed for GM2, GM3, GD2, and GD3, respectively. Our
experiments showed that the response ratio for each pair of MRM channels was practically
constant in standard-spiked solvent and unknown plasma extracts, confirming the identity
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of the monitored components. The optimized MS parameters for individual analytes are
given in Table 3.
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Table 2 The MRM transitions for quantification
Species

GM2

GM3

Positive Mode
Component
D18:1-14:0
D18:1-16:1
D18:1-16:0
D18:1-18:1
D18:1-18:0
D18:1-20:0
D18:1-12:0
D18:1-14:0
D18:1-16:1
D18:1-16:0
D18:1-18:1
D18:1-18:0
D18:1-20:0
D18:1-21:0
D18:1-22:0
D18:1-23:0
D18:1-24:0

MRM
Transition
665.1/204
678.1/204
679.1/204
692.1/204
693.1/204
707.1/204
549.3/274
563.3/274
576.3/274
577.3/274
590.3/274
591.3/274
605.3/274
612.3/274
619.3/274
626.3/274
633.3/274

Species

GD2

GD3
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Negative Mode
Component
D18:1-14:0
D18:1-16:0
D18:1-18:1
D18:1-18:0
D18:1-19:0
D18:1-20:0
D18:1-21:0
D18:1-22:0
D18:1-12:0
D18:1-14:0
D18:1-15:0
D18:1-16:1
D18:1-16:0
D18:1-17:0
D18:1-18:1
D18:1-18:0
D18:1-19:0
D18:1-20:0
D18:1-21:0
D18:1-22:0
D18:1-23:0
D18:1-24:0
D18:1-25:0

MRM
Transition
808.3/290
822.3/290
835.3/290
836.3/290
843.3/290
850.3/290
857.3/290
864.3/290
693.0/290
707.0/290
714.0/290
720.0/290
721.0/290
728.0/290
734.0/290
735.0/290
742.0/290
749.0/290
756.0/290
763.0/290
770.0/290
777.0/290
784.0/290

Table 3 Optimized MS parameters for individual ganglioside species
Positive Mode

Negative Mode

Analyte
GM2

GM3

GD2

GD3

Curtain Gas (Psi)

35.0

35.0

35.0

35.0

Collision Gas (Psi)

High

High

High

High

IonSpray Voltage (eV)

5400.0

5400.0

-4300.0

-4300.0

Temperature (℃)

500.0

500.0

600.0

600.0

Ion Source Gas 1 (Psi)

45.0

45.0

45.0

45.0

Ion Source Gas 2 (Psi)

45.0

45.0

45.0

45.0

Declustering Potential (eV)

65.0

65.0

-39.7

-45.7

Entrance Potential (eV)

7.0

7.0

-10.0

-10.0

Collision Energy (eV)

25.0

25.0

-50.0

-47.0

Collision Cell Exit Potential (eV)

20.0

20.0

-23.6

-21.5

MS Setting
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2.3.3 HPLC Conditions
Since multiple MRM transitions have been exploited to monitor each of the
four ganglioside species, a sufficient chromatographic separation between ganglioside
molecules and plasma interferences is essential to eliminate the potential ionization
suppression influence from the matrix for the acquisition of high quality quantification
during the analysis. Based on our preliminary studies during the method development, a
C18 reverse-phase UPLC column was found to provide the best resolution for multiple
ganglioside components. Under our optimized LC conditions, all the ganglioside
components were eluted out and spread within a retention time window from 3 to 9 minutes.
In general, gangliosides could be strongly retained by the C18 stationary phase due to the
hydrophobic nature of their ceramide portion. We observed that the use of
Methanol-Isopropanol (1:1) as the solvent of mobile phase B could elute the gangliosides
from the C18 stationary phase more effectively than the use of methanol only, and lead to
shorter chromatographic running time and better peak shapes. The MRM chromatograms
for the major components of GM3 ganglioside are shown in Fig.9.
It is noteworthy that the addition of 5 mM ammonium acetate in the mobile
phases considerably reinforced the peak intensities from all MRM channels in both positive
and negative ionization modes. This experimental phenomenon can be reasonably ascribed
to ammonium acetate’s ability to stabilize the pH at neural range, enabling both the
proton-donating interaction between ammonium group and gangliosides in the positive
mode and proton-accepting interaction between acetate group and gangliosides in the
negative mode to be undertaken for the promotion of ionizing efficiency during the
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electrospray ionization. While ammonium formate or formic acid was added into the
mobile phases, the responses from positive ionization was enhanced to a certain extent,
whereas substantial signal suppression was occurred in the negative ionization, which was
apparently attributable to intensified proton-donating tendency of formic acid and
ammonium formate as compared with ammonium acetate.
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Fig.9 Representative chromatograms for major components of GM3 in plasma extract
from a healthy subject.
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2.3.4 Sample Extraction Procedure
The most commonly used method for the isolation of gangliosides from
biomatrices is a liquid-liquid partition strategy that first reported by Svennerholm and
Fredman [6] for the treatment of human brain samples, which has been used or modified
later by other investigators [7, 8] for extracting gangliosides from milk and other matrices.
In brief, the workflow is constructed by the steps as following: (a) mixing the biomatrix
with chloroform/methanol/water (4:8:3) by vigorous shaking; (b) transferring the
ganglioside-enriched methanol/waster upper phase into a new container without disturbing
the middle and lower phase; (c) drying the crude extract with inert gas purging, and (d)
reconstituting the residues with methanol to a certain volume for quantitative analysis. To
compare the extraction recovery by using our simple protein-precipitation procedure and
the existed extraction method, we performed a series of parallel studies. In these assays,
analyte-free plasmas were spiked with the gangliosides followed by extraction with two
different extraction methods. As expected, our protein precipitation method was not only
easy-handling and time-saving, but also provided full recovery for all of the four
ganglioside species (Table 4). In contrast, the reported method generated insufficient
recovery for GM2 and GM3 gangliosides. According to the literatures, protein-precipitation
from plasma samples was commonly conducted by the addition of 3 to 4-fold of methanol
or acetonitrile, followed by high speed centrifugation. However, the widely adopted
condition generated unsatisfactory recovery of gangliosides from plasma. Based on modest
polarity of gangliosides from their hydrophilic oligosaccharide moiety and hydrophobic
ceramide portion, we attempted to achieve the best extraction recovery through adjustment
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of the polarity by increasing portion of methanol. Nearly 100% extraction recovery was
achieved for all of the four ganglioside species by the addition of 8-fold methanol into
plasma for protein precipitation.
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Table 4 Comparison of extraction recoveries between the reported method and our
protein-precipitation procedure (n=3)
Extraction Recovery (%)
Species

GM2
GM3
GD2
GD3

Protein-precipitation procedure
Recovery
CV
(Mean ± SD)
(%)
(%)
100 ± 8
7.83
94 ± 7
7.93
106 ± 9
8.69
99 ± 5
4.98
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Reported method
Recovery
CV
(Mean ± SD)
(%)
(%)
66 ± 6
9.70
41 ± 4
9.12
103 ± 5
4.46
102 ± 9
9.23

2.3.5 Standard Addition Calibration
According to the FDA guidelines for bioanalytical method validation [9], the
same type of matrix as actual samples should be used for the preparation of calibrators and
QCs during the quantitative method development and validation whenever feasible
concerning the potential pronounced signal interference imposed by the complex matrices.
For the determination of exogenous compounds that do not present in intended matrices,
the conventional standard calibration is usually employed to generate calibration curves
based on six or more levels of analytes spiked into analyte-free matrices. However, for the
measurement of endogenous compounds that originally present in the sample biomatrices
at significant concentrations, the standard addition calibration has been widely used for the
establishment of matrix-matched calibration. Commonly, each standard calibration curve is
constructed upon a set of 3-4 different concentrations prepared by addition (including a nil
addition) of known amounts of analyte standard into aliquots of a sample to be measured.
Recent publications involving the application of standard addition calibration include the
quantification of bile acids [10], sialic acids [11], gangliosides [5, 12], and other
endogenous compounds [13, 14, 15] in various biomatrices. In most of these studies,
including determination of gangliosides in milk and buttermilk, three or four points were
used to construct the calibration curves.
As indicated earlier, one of our objectives for the development of this assay is
to screen the ganglioside levels in plasma from patients with GM3 synthase deficiency
during clinical treatments. We have chosen three-level standard addition upon such a
consideration that these patients are mostly children or even infants, and that they can only
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provide small amounts of plasma for the study. As shown in Fig.6, the exemplified
calibration curves had R2 values in a range of 0.9998 - 1 for all four ganglioside species,
demonstrating a good linear relationship between the analyte response and concentration.
For the method validation, we prepared known-concentration samples by spiking
ganglioside standards into aliquots of analyte-free plasma from GSD patients. Analysis of
such known samples has shown that our assay employing the three-level standard addition
offered satisfactory precision and accuracy for the measurement of all the four ganglioside
species in plasma, which is detailed below.

2.3.6 Precision and Accuracy
The precision and accuracy for both intra-assay and inter-assay were assessed
by measuring analyte-free plasma samples spiked with the ganglioside standards in
triplicate. As shown in Table 5, the CV % for intra- and inter-assay of all measured
ganglioside species was within a range from 0.4 to 6 % with the relative error below 9 %.
Conclusively, the precision and accuracy of our quantitative method well fulfill the 15 %
error and variation tolerance as required by the FDA guidelines for bioanalytical method
validation [9].
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Table 5 Intra- and inter-assay precision and accuracy for the measurement of
gangliosides spiked in analyte-free human plasma from GSD patients (n=3)
Spiked
Species

Intra-assay

Inter-assay

conc

Measured

Precision

Accuracy

Measured

Precision

Accuracy

(ug/ml)

(Mean±SD)

(CV %)

(R.E. %)

(Mean±SD)

(CV %)

(R.E. %)

(ug/ml)

(ug/ml)

GM2

1.00

0.99±0.025

2.52

-0.60

1.04±0.059

5.67

4.45

GM3

4.53

4.45±0.019

0.42

-1.81

4.60±0.156

3.40

1.50

GD2

0.04

0.05±0.002

3.82

8.45

0.04±0.002

3.27

7.02

GD3

0.67

0.69±0.043

6.13

3.82

0.70±0.040

5.75

4.35
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2.3.7 Stability
The pre- and post- extraction stabilities of gangliosides in plasma under
various storage conditions were evaluated via the analysis of samples prepared from the
analyte-free plasma spiked with the gangliosides after undergoing the studied storage
conditions, and the results are listed in Table 6. The stability of “4-hour pre-extraction
storage at room temperature” was assessed by spiking gangliosides into the thawed
analyte-free plasma, letting the spiked samples stand at room temperature for 4 hours, and
then analyzing the samples via LC/MS immediately following the extraction procedure.
The stability of “8-hour post-extraction storage at room temperature” was evaluated by
spiking gangliosides into analyte-free plasma, extracting the spiked samples, letting the
extracts stand at room temperature for 8 hours, and then injecting them into LC/MS for
analysis. The measured stability values for the four ganglioside species range from 86 to
110 % under three different storage conditions, including one month pre-extraction at
-20 ℃, 4-hour pre-extraction at room temperature, and 8-hour post-extraction at room
temperature. Apparently, the gangliosides were stable in the plasma at the stages of frozen
storage, sample treatment, and analysis.
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Table 6 Stabilities of gangliosides in human plasma under various storage conditions
(n=3)

Storage conditions
One month pre-extraction storage at -20 ℃
4-hour pre-extraction storage at room temperature
8-hour post-extraction storage at room temperature
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Recovery
(Mean ± SD)
(%)
GM2
GM3
GD2
GD3
104 ± 9 90.5 ± 8 84.2 ± 5 86.5 ± 4
96.3 ± 7 98.6 ± 2 86.2 ± 7 88.8 ± 6
101 ± 3 106 ± 1 106 ± 5 110 ± 6

2.3.8 Matrix Effect
The matrix effect for mass spectrometry detection of gangliosides was assessed
through comparable analysis of analyte-free plasma extracts spiked with ganglioside
standards and the pure solvent spiked with such standards at the same contractions in
triplicate. It was found that the matrix impurities substantially suppressed the ganglioside
signals, and the LC/MS/MS peak areas from the plasma extracts were only 61.3, 36.0, 68.3,
and 49.0% in comparison to the pure solvent for ganglioside GM2, GM3, GD2, and GD3,
respectively. By using the standard addition calibration, the matrix effect practically had no
influence on the measurement because the same matrix was utilized for the calibrators and
the relevant samples, which was proven by the high linearity of calibration, precision, and
accuracy.

2.3.9 Method Application
The validated LC/MS/MS assay has been successfully applied to determine
ganglioside concentrations in human plasma from different specimens, including 20 normal
human subjects and 6 GSD patients. As shown in Table 7, the averaged ganglioside levels
in the plasma samples from 20 normal human subjects (include 12 males and 8 females)
were 2.37, 9.72, 0.01, and 1.80 µg/ml for GM2, GM3, GD2, and GD3, respectively. In
contrast, the analyte-free plasma from 6 patients with GSD had no gangliosides presented
at the measurable level, which was consistent with the pathological manifestation of the
neurodegenerative disorder. The averaged GM3 concentration in plasma samples from
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eight healthy human subjects determined by a published LC/MS method [13] was 7.2
µg/ml, which was quite comparable to our result (9.72 µg/ml).

2.4 Conclusion
This study detailed the development and validation of a sensitive LC/MS/MS
method for the determination of gangliosides GM2, GM3, GD2, and GD3 in human plasma.
This method utilized a simple protein-precipitation procedure for rapid extraction of the
gangliosides from the matrix, UPLC for high resolution chromatographic separation, and
multiple MRM transitions for sensitive and specific mass spectrometric detection, which
had been successfully applied to determine the level of gangliosides in plasma from normal
human subjects. Considering the quickness, sensitivity, and specificity of this assay, we
believe that it is also applicable to other potential biomatrices with some appropriate
modifications.

65

Table 7 The ganglioside plasma concentrations from human specimens

Subjects

Total

Normal Adults
20
GSD Patients
6
NM – Not Measurable

GM2
(Mean ± SD)
(µg/ml)
2.37 ± 0.79
NM

Averaged Levels
GM3
GD2
(Mean ± SD) (Mean ± SD)
(µg/ml)
(µg/ml)
9.72 ± 3.68
0.01 ± 0.01
NM
NM

66

GD3
(Mean ± SD)
(µg/ml)
1.80 ± 0.64
NM

2.5 Future Direction
The quantitative method established in this study has been known to be the
first LC-MS/MS method for quantification of gangliosides in human plasma with full
method validation under FDA guideline for bioanalytical method development. It utilizes a
simple protein precipitation procedure for the analyte extraction and a matrix-matched
standard addition calibration based on three levels for the measurement of analytes in the
plasma matrix. However, a number of factors have practically limited this method from
being broadly applied into the routine analysis in the clinical laboratory.
To begin with, depending on the sugar components present in their
carbohydrate moieties, monosialoganglioside molecules generally have molar mass ranging
from 1200 to 1600 Da, making the majority of their singly charged molecular ions being
undetectable by our instrument (dynamic range 50~1250 m/z). Considering carboxyl group
on the sialic acid residue serves as the sole ionization site on their chemical structures, their
chances of undergoing dual protonation/deprotonation to generate doubly charged
molecular ions have been found to be extremely difficult during the electrospray ionization,
leading to their very low detection sensitivities during the analysis. So, from the clinical
perspective, this method would be very promising and reliable for clinical diagnosis on the
screening of ganglioside-related disorders from newborns, but not quite applicable to
pharmacokinetic studies during the clinical trial where sufficient detection sensitivity from
the analysis is typically required to draw solid and unarguable conclusions.
In addition, the clinical study usually requires certain degree of throughput
from the analytical method to ensure collected samples would be handled in a very timely
67

manner and facilitate the decision-making as well as problem solving. Unfortunately, due
to the nature of standard addition calibration method, a single sample is required to be
analyzed repetitively in triplicate for this case in order to establish the calibration curve that
dedicated for this particular sample, which is extremely laborious and time-consuming,
making this method more preferable for diagnostic purpose rather than routine clinical
analysis in terms of analytical throughput.
Last but not the least, the introduction of protein precipitation strategy for
sample extraction significantly simplifies the experimental procedure through which the
plasma sample is processed and reduces the time needed for sample preparation prior to the
analysis. However, the simplicity of protein precipitation strategy might also adversely
affect the quality of analysis by retaining the majority of the matrix interferences in the
plasma extract along with the analyte. As can be seen during the application of this method,
the increased abundance of matrix interferences in the post-extraction extract tends to
accumulatively build up on the analytical column over several hundreds of injections and
thus jeopardize the separation performance over time, leading to the significantly increased
analytical cost as the column has to be replaced in a more frequent manner.
As a result, since this method was initially developed and validated solely for
facilitating the screening and diagnosis of GSD on the upcoming newborns from the Amish
families, the sample preparation method, chromatographic separation method, and the mass
spectrometric detection method have been thoroughly simplified in order to accomplish the
rapidness and efficiency of the analysis according to the time frame needed by clinical
studies. However, the flip side of this method is that it maintains the analytical quickness of
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the method while sacrifices the certain degree of the detection sensitivity and specificity,
which impedes us from further applying this method to answering the major questions
remaining in the ongoing clinical studies. In order to further overcome those challenging
issues, improvements on the method performance are needed to take place in order to
successfully circumvent the major challenges imposed by stringent requirements of clinical
studies on specificity, sensitivity, and throughput of bioanalytical methodology.
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CHAPTER Ⅲ

QUANTIFICATION OF MONOSIALOGANGLIOSIDES IN HUMAN PLASMA
THROUGH CHEMICAL DERIVATIZATION FOR SIGNAL ENHANCEMENT IN
LC-ESI-MS

3.1 Introduction to Chemical Derivatization Methods for Sialic Acid Neu5Ac and
DMTMM&PAEA-Based Amidation
Sialic acids are a big family of N-/O-substituted derivatives of neuraminic acids
that characterized by the presence of nine-carbon scaffold as their structural backbone.
Currently, there have been over 43 derivatives from the sialic family identified to exist freely
in the nature, three of which act as the predominant species in the entire population,
N-acetylneuraminic

acid

(Neu5Ac),

N-glycolylneuraminic

acid

(Neu5Gc),

and

2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN). Based on up-to-date knowledge,
Neu5Ac has been found to be the only sialic acid species that virtually presenting in the
carbohydrate terminus of glycosphingolipids, especially gangliosides. Their individual
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chemical structures can be found in Fig.10. Depending on the identity of monosaccharide
unit to which Neu5Ac is bound, it could be linked with neighboring monosaccharide units
through either α2-3 or α2-6 linkage in gangliosides. Biologically, sialic acids usually serve
as a surface clutch at the terminal position of carbohydrate moiety of glycoprotein receptors
to mediate the intracellular signaling cascade triggered by extracellular ligand-binding
events. Its biological role in acting as a cell surface regulator to extracellular signaling has
been prevalently found in a wide variety of essential cellular events, including cell-cell
recognition [1-3], cell differentiation [4-6], and antigen-mediated immunological response
[7-9].
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Fig.10 Structures of sialic acid Neu5Ac, Neu5Gc, and KDN
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Owing to its biological versatility in the physiological system, substantial
studies have been done on the analytical methodology to enable the quantitative analysis of
this fascinating molecule with promising sensitivity and specificity in various biological
systems under different physiological conditions in the past decades. However, some of the
early trials were failed to reach the concentration at which the level of Neu5Ac with
biological significance could be reliably measured because its highly hydrophilic nature
makes it fairly easy to interfere with other structural analogs during the analysis.
Fortunately, the advent of mass spectrometry interfaced to high performance liquid
chromatography in recent years has given rise to improved sensitivity and specificity of the
analysis, whereas its mass spectrometric analysis still remain challenging and problematic.
As a result, a number of derivatization methods have also been developed and introduced to
practically circumvent the challenges faced by analytical chemist and analytically facilitate
its mass spectrometric analysis.
As reviewed previously by Huan, Nie et al [10], the both bound- and
unbound-Neu5Ac could undergo derivatization to obtain enhanced ionization in its mass
spectrometric analysis. Particularly, for the analysis of bound-Neu5Ac, same as in the case
for the analysis of gangliosides, esterification and amidation are two most commonly used
reactions for the derivatization of Neu5Ac-containing molecules as shown in Fig.11.
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Fig.11 Structures of sialic acid derivatives [10].
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In consideration of our urgent demand in significantly enhancing the detection
sensitivities from monosialogangliosides on the LC-ESI-MS, the amidation reactions with
the option to attach additional proton acceptors/donors onto the chemical structures of
monosialogangliosides would thus be a more preferable and advantageous choice over the
esterification reaction from the sensitivity enhancement perspective. Among multiple
available options for amidation reactions, 2-(2-Pyridilamino)-ethylamine (PAEA) & 4-(4,
6-Dimethoxy-1, 3, 5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) amidation
characterized by simultaneous attachment of two proton-accepting groups following the
reaction confers the capability of this reaction to convert singly-charged-favorable
monosialogangliosides to doubly-charged-favorable PAEA-monosialogangliosides in ESI
positive through a one-step chemical modification, suggesting its tremendous potential in
resolving this particular problem.
DMTMM&PAEA-based amidation reaction was first introduced by Shin-ichi
Endo et al. [11] to derivatize a group of Neu5Ac-containing molecules, including
3’-sialyllactose, 6’-sialyllactose, and ganglioside GM3, and enhance their detection signals
in MALDI-TOF. Based on the molecular mechanism of the reaction, DMTMM chemically
serves as an activator of the carboxylic acid group by forming the DMTMM-Neu5Ac
active ester intermediate through nucleophilic substitution, which allows the occurrence of
the subsequent amidation on the esterified carboxylic acid group through another round of
necleophilic substitution to form an amide bond with the head aliphatic amine group from
PAEA. The alkaline pyridylamine group at the other end of PAEA confers the capability to
Neu5Ac residue for undergoing double pronation under either ESI+ or MALDI+ by
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increasing its ability to capture dual protons during the ionization, which shifts its
ionization profile from predominantly singly charged to primarily doubly charged in terms
of its charging pattern. In addition, since the pyridylamine group is less alkaline than the
alphatic amines group on PAEA, this disparate property on alkalinity gives rise to the
orientational selectivity on the reaction, which also prevents the further coupling of another
carboxylic group onto the amidated PAEA. From this study, they have demonstrated that
multiple times reinforcements on MS responses were observed from PAEA derivatives of
3’-sialyllactose, 6’-sialyllactose, and ganglioside GM3. Based on their results, the
DMTMM&PAEA-based amidation was able to be undertaken through a one-pot reaction
under mild conditions at room temperature with continuous stirring. However,
unsatisfactorily, the reaction yield they ended up with 3-hour reaction in the 90%
isopropanol system for 3’-sialyllactose, 6’-sialyllactose, and ganglioside GM3 were 45%,
60%, and 30%, respectively, which leaves a plenty of room for further improvement on the
conditions under which the reaction takes place before it could virtually be applied to mass
spectrometrically analyze the monosialoganglioside from the quantitative standpoint.
As a result, in the present work, we have developed and validated a new
UPLC-MS/MS method with enhanced sensitivity for the measurement of three
monosialoganglioside species (GM1, GM2, and GM3) in human plasma using
PAEA&DMTMM-based derivatization. The conditions under which the PAEA&DMTMM
reaction occurs have been re-optimized based on solvent, reaction time, reagent
concentration, and reaction temperature to achieve above 90% reaction yield for
monosialogangliosides. This method employed reverse phase UPLC for chromatographic
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separation and tandem mass spectrometry in the MRM mode for superior detection
sensitivity and specificity. The ESI-MS responses of the three monosialoganglioside
species were enhanced by more than 15 times following PAEA&DMTMM-based
derivatization. We have successfully applied this method to the determination of
monosialoganglioside levels in human plasma from GSD patients, carriers and normal
adults.

3.2 Materials and Methods

3.2.1 Materials
Derivatization reagents 4 - (4, 6 – Dimethoxy - 1, 3, 5 – triazin – 2 - yl) – 4 methylmorpholinium chloride (DMTMM) and 2 - (2 - Pyridilamino) ethylamine (PAEA)
were purchased from Sigma Aldrich (St. Louis, MO) and Santa Cruz (Dallas, TX),
respectively. Calibration standards GM1, GM2, and GM3 were obtained from EMD
Chemicals (Billerica, MA) and Avantilipids (Alabaster, AL). Internal standards (ISs)
N-omega-CD3-Octadecanoyl monosialogangliosides GM1 (2D3-GM1), GM2 (2D3-GM1),
and GM3 (2D3-GM3) were purchased from Matreya LLC (Pleasant Gap, PA). HPLC grade
methanol, acetonitrile, and isopropanol were obtained from EMD Milipore (Billerica, MA).
HPLC grade formic acid was obtained from Fisher Scientific (Pittsburgh, PA). Deionized
water was prepared using the Barnstead Nano-PURE Water Purification System (Asheville,
NC). All materials were used directly without further purification.
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3.2.2 Human Plasma
The study was approved by the DDC Clinic Institutional Review Board, and
written consents were obtained from the study subjects or their legal guardians. The
genotypes of the studied patients were determined through DNA sequencing and mutation
analysis. The human plasma samples were stored at -20℃before analysis.

3.2.3 Stock and Working Solutions
Stock solutions of DMTMM and PAEA were prepared by dissolving the
lyophilized powders in 1:1 MeOH/Isopropanol to obtain concentrations of 1 M, and their
working solutions with concentrations of 100 mM were obtained by serial dilution with 1:1
MeOH/Isopropanol.
Stock solutions of GM1, GM2, and GM3 were prepared by dissolving the
lyophilized powders in 90% MeOH to obtain equal concentrations of 0.250 mg/mL. The
seven-level working solutions, which also served as calibrators, were prepared though
serial dilution with 90% MeOH to obtain concentrations of 10.0, 20.0, 50.0, 1.00×102,
4.00×102, 1.00×103, 2.00×103 ng/mL for GM1, 10.0, 20.0, 50.0, 1.00×102, 4.00×102,
1.00×103, 2.00×103 ng/mL for GM2, and 80.0, 1.60×102, 4.00×102, 8.00×102, 3.20×103,
8.00×103, 1.60×104 ng/mL for GM3. The preparation of three-level QC working solutions
was carried out in a similar manner to obtain concentrations of 25.0, 2.50×102, 1.60×103
ng/mL for GM1, 25.0, 2.50×102, 1.60×103 ng/mL for GM2, and 2.00×102, 2×103, 1.28×104
ng/mL for GM3. Likewise, stock solutions of Iss 2D3-GM1, 2D3-GM1, and 2D3-GM3 were
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prepared by dissolving the lyophilized powders in 90% MeOH to obtain concentrations of
0.250 mg/mL. The IS working solution was prepared by dilution of the corresponding stock
solution with 90% MeOH to provide a concentration of 5.00×102 ng/mL for each IS.
The low plasma QC working solution was prepared by pooling plasma samples
from multiple GSD patients and dividing the pool into 20 µL aliquots. The high plasma QC
working solution was prepared by pooling plasma samples from normal adults and dividing
the pool into 20 µL aliquots.
All prepared stock and working solutions were kept at -20℃before use.

3.2.4 Sample Preparation
For plasma sample, 20 µL of plasma was taken and spiked with 10 µL of IS
working solution. Afterwards, the spiked samples were subjected to sample extraction
phase described below.
For calibration, each of calibrators was prepared by individually mixing 10 µL
of a corresponding calibrator working solution with 10 µL IS working solution. The
calibrators were then subjected to sample derivatization phase described below.
During the sample extraction phase, the spiked plasma samples underwent
protein precipitation with the addition of 190 µL methanol as described previously [12].
The supernatant was transferred into a 1.7-mL plastic centrifuge vial for subsequent
extraction. Thereafter, 200µL of water and 160 µL of chloroform were added to the
supernatant. After vortexing, the mixture was centrifuged at 10,000 g for 3 min to separate
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the liquid into two phases. The upper phase was transferred into a new 1.7-mL centrifuge
vial. Subsequently, the extraction was repeated twice for the lower phase with 200 µL of
MeOH and 200 µL of water for each trial, and the extracts were combined and subjected to
the derivatization phase.
During the sample derivatization phase, each sample (plasma extract/calibrator)
was dried under a continuous nitrogen stream, and reconstituted with 40 µL of isopropanol.
Thereafter, 12 and 48 µL of PAEA and DMTMM working solutions, respectively, were
added into the reconstituted sample. Then, the reaction mixture was vortexed to mix
thoroughly, and incubated at 80℃ on the heat block for 40 min. After the incubation, the
sample vial was removed and placed onto the ice bath to terminate the reaction. Once
cooled, 100 µL of isopropanol was added to dilute the reacted mixture to a total volume of
200 µL. Following vortexing, the mixture was centrifuged at 5,000 g for 1 min, and the
supernatant was transferred into an auto-sampler vial with a micro-insert for LC/MS
analysis.

3.2.5 LC/MS Instrumentation
The UPLC system was composed of a DGU-20A3R degasser, two LC-30AD
pumps, a SIL-30AC autosampler, a CTO-10A column oven and a CBM-20A system
controller from Shimadzu (Columbia, MD). The UPLC system was interfaced to a Qtrap
5500 mass spectrometer equipped with an electrospray ionization source and a built-in
Valco switch valve from AB SCIEX (Framingham, MA). The Multiple Reaction
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Monitoring (MRM) mode was utilized for quantitation. Individual MRM transitions have
been given in Table 8. The MS parameters for individual PAEA-monosialogangliosides
have been given in Table 9. Data acquisition and chromatographic peak integration were
conducted using the Analysis 1.6.1 software package from AB SCIEX.
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Table 8 The MRM transitions for quantification of PAEA-monosialogangliosides
Collision
Species

Energy

Component

eV

PAEAGM1

PAEAGM2

39.9

34.9

Collision

MRM

Species

Transition

Energy

Component

eV

MRM
Transition

d18:1-14:0

805.6/411.2

d18:1-14:0

622.9/411.2

d18:1-16:1

818.6/411.2

d18:1-16:1

635.9/411.2

d18:1-16:0

819.6/411.2

d18:1-16:0

636.9/411.2

d18:1-18:1

832.6/411.2

d18:1-18:1

649.9/411.2

d18:1-18:0

833.6/411.2

PAEA-

d18:1-18:0

650.9/411.2

d18:1-20:0

847.6/411.2

GM3

d18:1-20:0

664.9/411.2

d18:1-16:0

738.7/411.2

d18:1-21:0

671.9/411.2

d18:1-18:1

751.7/411.2

d18:1-22:0

678.9/411.2

d18:1-18:0

752.7/411.2

d18:1-23:0

685.9/411.2

d18:1-20:0

768.7/411.2

d18:1-24:0

692.9/411.2
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33.0

Table 9 MS parameters for individual PAEA-monosialogangliosides
Analytes
PAEA-GM1

PAEA-GM2

PAEA-GM3

Curtain Gas (Psi)

30.0

30.0

30.0

Collision Gas (Psi)

High

High

High

IonSpray Voltage (eV)

5000.0

5000.0

5000.0

Temperature (℃)

600.0

600.0

600.0

Ion Source Gas 1 (Psi)

35.0

35.0

35.0

Ion Source Gas 2 (Psi)

35.0

35.0

35.0

Declustering Potential (eV)

83.0

93.0

57.9

Entrance Potential (eV)

8.1

11.1

12.6

Collision Energy (eV)

39.9

34.9

33.0

Collision Cell Exit Potential (eV)

36.0

34.5

32.7

MS Parameters
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3.2.6 LC-MS/MS Procedure
Following chemical derivatization, 10 µL of sample was injected onto a
Kinetex-C8 UPLC column (1.7 µm, 50 mm × 2.1 mm; Phenomenex, Torrance, CA)
guarded with a C8 Security Cartridge. The mobile phases used were a mixture of 2%
MeOH with 1% formic acid (A) and ACN-MeOH (6:4) with 1% formic acid (B). The
chromatographic separation was implemented employing a gradient elusion program.
Briefly, the initial B% was maintained at 50% for 1 min and steeply increased to 75% at 1.5
min followed by a linear increase to 95% at 7 min. Thereafter, the B% was held constant at
95% for an additional 1.5 min and then dropped immediately to 50% for remainder of the
run. In addition, the LC eluent at 0.3 mL/min was directed into the waste during the first
4.5 minutes and then introduced into the electrospray ionization source from 4.6 to 8.0
minutes as all derivatized monosialoganglioside components were sequentially eluted and
detected. Thereafter, the flow rate was increased to 0.6 mL/min to rapidly clean up and
re-equilibrate the column for the next run. The temperatures of auto-sampler and column
oven were maintained at 4 and 35℃, respectively, throughout the analysis.

3.2.7 Calibration Curve
Quantitation of the gangliosides in plasma samples was conducted using
calibration curves based on seven levels. For each of the three monosialoganglioside
species, the total peak area was calculated by summing up the IS-normalized peak areas of
individual components based on a single injection.
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The seven-level calibration curves were then established by plotting the
IS-normalized total peak area of each measured monosialoganglioside species as the y-axis
against the concentration levels of seven-level calibrators as the x-axis. The linear
regression with a weighting factor of 1/y2 was employed. The calculated equation was
applied to the measurement of monosialoganglioside levels in plasma sample. The standard
calibration curves for measured monosialoganglioside species have been shown in Fig.12.
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Fig.12 Calibration curves for GM1 (A), GM2 (B), and GM3 (C).
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3.3 Results and Discussion

3.3.1 Derivatization Conditions
Since the carboxylic acid group on the sialic acid residue bears high preference
to lose a proton, negative ESI is thus a more common option in generating singly charged
molecular ions of monosialogangliosides than positive ESI in terms of ionization efficiency.
However, considering their high molecular weight, the m/z values of singly charged
molecular ions of major monosialoganglioside species are virtually beyond the detection
range of many commercially available triple-quadrupole mass spectrometers, including our
instrument. Therefore, the selection of corresponding doubly charged molecular ions with
detectable m/z values has been a more practical approach to analyze these molecules with
such instruments. Based on our preliminary studies, the absence of an additional proton
donating/accepting group on native structures of monosialogangliosides impedes them to
undergo the dual proton transferring pathway during ionization, which accounts for the low
tendency of accepting/donating two protons by monosialogangliosides in ESI and the
insufficient generation of doubly charged molecular ions in their MS profile, resulting in
limited detection sensitivity. In order to overcome the limitation, modifications on their
native structures are needed to increase the efficiency in generating corresponding doubly
charged molecular ions in ESI.
The PAEA&DMTMM-based derivatization was first reported by Shin-ichi
Endo et al. [11] for signal enhancement in the analysis of sialic acid Neu5Ac and
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ganglioside GM3 using MALDI-TOF. From this study, multiple times reinforcement on
MS response was observed from the PAEA-GM3. However, it was discovered that the
derivatization yields of GM1, GM2, and GM3 were extremely poor (< 35%) under the
reported conditions. In order to overcome this limitation, we optimized reaction conditions
in terms of reagent concentration, reaction time, reagent ratio, reaction solvent, as well as
instrumental conditions to achieve a maximal LC/MS peak area from the analytes. As
shown in Fig.13, we found that 60mM PAEA and 60mM DMTMM provided the maximal
LC peak area for all measured monosialoganglioside species. In addition, 40min was found
to be the most favorable time for the reaction. Moreover, in consideration of the reaction
mechanism, amidation is essentially a typical endothermic reaction with the stringent
threshold on the temperature under which the reaction is undertaken, suggesting the
directly proportional relationship between the reaction yield and temperature. Based on this
rationale, the reaction temperature was optimized to 80 ℃in accordance to the boiling point
of the solvent mixture. Under the optimized conditions, the reaction yield was observed to
be above 90%. With this derivatization, we observed over 15-time signal enhancement
compared to the previous method [12] due to the abundance of doubly charged molecular
ions in positive ESI. This beneficial effect could be attributed to the addition of a
pyridylamine group, a preferable dual-proton acceptor. The reaction scheme has been
elaborated in Fig.14.
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B
A
C

Fig.13 Optimization of reaction conditions
The conditions were optimized based on (A) reagent ratio, (B) reagent concentration, and
(C) reaction time.
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3.3.2 Mass Spec Conditions
The representative product ion mass spectra of d18:1-20:0 components for
GM1, GM2, and GM3 were shown in Fig. 3.6. As illustrated by their MS/MS profiles,
monosialogangliosides appeared to share certain degree of similarities in their
fragmentation patterns, including common fragments m/z = 411.2 and 573.2, corresponding
to fragments [PAEA-Neu5Ac+H]+ and [PAEA-Neu5Ac-Gla+H]+, respectively, confirming
the desired position has been preferentially derivatized. In addition, the universal fragment
m/z=411.2 was observed to be the most abundant among any other fragments present in the
MS/MS profiles of PAEA-monosialogangliosides.
After evaluating the quality of different possible precursor → daughter ion
pairs for quantitation, we found that the following MRM transitions provided the optimal
quantitative

performance

in

terms

of

detection

sensitivity

and

specificity:

[PAEA-GM1+2H]2+ → 411.2 for GM1, [PAEA-GM2+2H]2+ → 411.2 for GM2, and
[PAEA-GM3+2H]2+ → 411.2 for GM3. Moreover, transitions [PAEA-GM1+2H]2+ →
573.2, [PAEA-GM2+2H]2+→ 573.2, and [PAEA-GM3+2H]2+ → 573.2 were also
monitored for quality assurance. The monitored MRM transitions for quantitation have
been listed in Table 10. The fragmentation mechanisms for GM1, GM2, and GM3 have
been interpreted and elaborated in Fig.15.
In addition, since sialic acid residues are well known to be fragile during
electrospray ionization, in-source loss of sialic acid residues has been the primary concern
associated with the analysis of sialic acid-containing molecules employing ESI-MS.
Therefore, in order to determine the degree of in-source sialic acid loss during ESI, we
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carried out a series of experiments by individually injecting the derivatized standards into
the LC and implementing MS full scan on Q3 under our experimental conditions. Based on
the MS spectra we obtained at the retention times of our analytes (data not shown), the
amount of PAEA-monosialogangliosides that underwent in-source loss was found to be
insignificant during the ionization process.
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Fig.15 The product ion (MS/MS) spectra for d18:1-20:0 components of
PAEA-monosialogangliosides
MS/MS spectra for PAEA-GM1 (A), PAEA-GM2 (B), and PAEA-GM3 (C)
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N

3.3.3 HPLC Conditions
Due to the chemical complexity of monosialoganglioside species, an
appropriate chromatographic separation with one component being resolved and separated
from another is essential to avoid the competition for ionization between co-eluates and to
eliminate potential ionization suppression from matrix interferences during analysis. Based
on our preliminary study, the analytes generally showed good resolution on separation but
appeared to be overwhelmingly retentive on the C18 stationary phase. This was probably
due to their elevated hydrophobicity after derivatization, which not only widened the
chromatographic peak of individual components, but also prolonged the analysis time. In
comparison, the C8 stationary phase with lower hydrophobicity was observed to retain the
analytes less vigorously, enabling sharper chromatographic peaks and a shorter LC run
without sacrificing the separation resolution. The addition of acetonitrile to mobile phase B
significantly reduced the retention of the analytes on the C8 stationary phase and
effectively shortened the chromatographic run in comparison with methanol only, leading
to better peak shape and faster analysis. On the other hand, the certain portion of methanol
was necessary to maintain the analytes to be solubilized in the mobile phase during the
analysis. Therefore, the ratio of acetonitrile to methanol was optimized at 6 to 4 for the best
chromatographic

performance.

Under

our

optimized

LC

conditions,

different

monosialoganglioside components were spread in a chromatographic window from 4.5 to 8
min. Chromatograms for PAEA-GM3 are shown in Fig.17.
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Fig.17 MRM chromatograms for different components from PAEA-GM3
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It is worth noting that the addition of 1% formic acid to the mobile phase
substantially enhanced the peak intensities from all MRM transitions by multiple times in
positive ESI. This experimental phenomenon could be reasonably explained by the
increased proton donating capability of the mobile phase upon the introduction of formic
acid, allowing the dual-proton acceptance of PAEA-monosialoganglioside to be achieved at
an elevated level in positive ESI. Expectedly, the reinforcement in MS response was
observed to be less significant by the addition of ammonium formate and ammonium
acetate in comparison with formic acid. This was due to their inability to further lower the
pH of the mobile phase below the level that has been achieved by formic acid.
In addition, the addition of 1% formic acid into the mobile phase considerably
reduced the buildup of derivatizing reagents on the column solid phase. This was due to
enhanced ionization of leftover DMTMM&PAEA, thereby decreasing their retention on the
stationary phase, resulting in the consistency and reproducibility of separation performance
from the column over time.

3.3.4 LLOQ, Precision and Accuracy
The LLOQ, defined as S/N near or above 10, for each analyte was determined
by analyzing samples prepared from 5 individual lots of plasma spiked with their
corresponding deuterium-labeled siblings. The LLOQs were 10, 10, and 80 ng/mL for GM1,
GM2, and GM3, respectively, demonstrating the specificity and sensitivity of this assay for
the accurate determination of monosialogangliosides in human plasma.
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The precision and accuracy for intra-assay and inter-assay measurements were
assessed by analyzing QC standards prepared at three different concentrations in five
replicates. As shown in Table 10, the coefficient of variation (CV %) and relative error
(RE %) for intra- and inter-assay measurements were within 9% and 11%, respectively. In
addition, the precision for intra-assay and inter-assay measurements in the plasma matrix
was also evaluated by analyzing samples prepared from five individual lots of high and low
plasma QCs from unaffected adults and GSD patients on a single day and five different
days, respectively. As shown in Table 11, the CV% from both high and low plasma QC
measurements were found to be below 15% as required by the FDA guidelines for
bioanalytical method validation [13].
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Table 10 Intra- and inter-assay precision and accuracy for the measurement of QC
standards (n=5)
Intra-assay

Spiked
Species

GM1

GM2

GM3

QC

Inter-assay

Conc

Mean ± SD

Precision

Accuracy

Mean ± SD

Precision

Accuracy

(ng/ml)

(ng/ml)

(CV %)

(R.E. %)

(ng/ml)

(CV %)

(R.E. %)

Low

25.0

27.7±0.90

3.0

11

27.3±1.7

6.0

9.0

Mid

2.50×102

(2.63±0.18) ×102

7.0

6.0

5.0

10

High

1.60×103

(1.43±0.13) ×103

9.0

-11

3.0

-1.0

Low

25.0

23.4±1.9

8.0

-6.0

2.0

0

Mid

2.50×102

4.0

-6.0

3.0

-3.0

High

1.60×103

2.0

1.0

7.0

4.0

Low

2.00×102

7.0

5.0

4.0

5.0

Mid

2.00×103

4.0

3.0

3.0

3.0

High

1.28×104

4.0

-2.0

5.0

-3.0

(2.35±0.099)
×10

2

(1.62±0.040)
×103
(2.09±0.14)
×10

2

(2.06±0.080)
×103
(1.26±0.050)
×104

101

(2.74±0.15)
×102
(1.58±0.040)
×103
25.0±0.60
(2.42±0.081)
×102
(1.67±0.11) ×103
(2.11±0.083)
×102
(2.06±0.060)
×103
(1.26±0.060)
×104

Table 11 Intra- and inter-assay precision for the measurement of plasma QCs (n=5)
Species
GM1
GM2
GM3

QC
Low
High
Low
High
Low
High

Intra-assay
Mean±SD
Precision
(ng/ml)
(CV %)
987±59
6
962±89
9
ND
N/A
308±12
4
54.4±3.0
5
(9.05±0.58)
6
×103

Inter-assay
Mean±SD
Precision
(ng/ml)
(CV %)
879±118
13
920±112
12
ND
N/A
302±33
11
46.7±6.6
14
(9.65±1.41)
15
×103

Note:
1. Due to the nature of GSD and reverse phase LC, no ideal low plasma QC was currently
available for GM1
2. Each of low plasma QC was prepared from 20m L of patient plasma spiked with 10m L
of IS work solution
3. Each of high plasma QC was prepared in a similar manner except the plasma was
sample from unaffected adult
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3.3.5 Stability and Extraction Recovery
Since stabilities of gangliosides in plasma under various storage conditions had
already been evaluated by our previous studies [12], only the autosampler storage stability
of PAEA-monosialogangliosides was evaluated in this study by analyzing samples prepared
from five individual lots of plasma from GSD patients spiked with deuterium-labeled
standards at QC concentrations before and after overnight storage at 4 ℃. The stability
values for the three monosialogangliosides were about 100% under such conditions as
shown in Table 12, indicating no significant loss of any analytes under the storage
condition of autosampler.
The extraction recoveries for all monosialogangliosides were assessed by
comparably analyzing samples prepared from five individual lots of plasma from GSD
patients spiked with deuterium-labeled standards at QC concentrations in both pre- and
post-extraction stages. As shown in Table 12, about 80~100% of analytes were recovered
from the plasma matrix at the studied concentrations, indicating the effectiveness of our
optimized sample extraction procedure.
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Table 12 The stability of PAEA-monosialogangliosides and extraction recovery of
monosialogangliosides from plasma samples at QC concentrations (n=5)
Species

GM1

GM2

GM3

QC
Low
Mid
High
Low
Mid
High
Low
Mid
High

Spiked
Concentration
(ng/ml)
25.0
2.50×102
1.60×103
25.0
2.50×102
1.60×103
2.00×102
2.00×103
1.28×104

Autosampler Stability
Mean ± SD
CV
(%)
(%)
103±7.0
7.0
101±8.0
8.0
102±3.0
3.0
104±13
12
107±3.0
3.0
100±3.0
3.0
100±10
10
103±5.0
5.0
100±4.0
4.0
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Extraction Recovery
Mean ± SD
CV
(%)
(%)
94.0±7.0
8.0
84.0±3.0
4.0
80.0±2.0
3.0
84.0±3.0
4.0
83.0±2.0
3.0
81.0±6.0
7.0
102±4.0
4.0
83.0±8.0
10
80.0±6.0
8.0

3.3.6 Method Application
The validated method was successfully applied to measure the levels of
monosialogangliosides in plasma samples from different specimens, including unaffected
adults, GSD heterozygous carriers, and GSD patients, during the ongoing clinical study. As
shown in Table 13, the plasma levels of monosialogangliosides from 31 normal adults were
(1.35±0.39) × 103, (4.71±1.8) × 102, and (9.93±2.9) × 103 ng/mL for GM1, GM2, and GM3,
respectively. In comparison, averaged monosialoganglioside levels in plasma samples from
12 heterozygous carriers were (7.12±2.4) × 102, (2.38±1.0) × 102, and (6.23±1.9) × 103
ng/mL for GM1, GM2, and GM3, respectively, slightly lower than those unaffected
subjects, which is consistent with results reported by previous studies [14].
In comparison with plasma concentrations from measurements on unaffected
adults and GSD patients by the diagnostic method established in chapter 2, the measured
values of GM3 in plasma samples from unaffected adults determined by the new method
(9.93±2.9 µg/mL) was found to be comparable with the previous results (9.72±3.68 µg/mL),
whereas significant variation was noticed from the measured values of GM2 on unaffected
adults between two different methods (0.47±0.18 versus 2.37±0.79 µg/mL), which could be
possibly attributed to the physiological variance on GM2 abundance in blood circulations
of people from disparate populations.
Interestingly, as a result of the enhanced sensitivity produced by the chemical
derivatization of monosialogangliosides with DMTMM&PAEA, we detected a significant
amount of GM3 in the plasma of GSD patients with the newly developed method. As
shown in Table 3.5, the level of GM3 from 12 of 14 GSD patients (2 patients remained
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immeasurable) averaged (1.13±0.33)×102 ng/mL, while the level of GM2 remained
undetectable. Although the amount of GM3 in the plasma of the GSD patients was small,
accounting for approximately 1% of plasma abundance of GM3 in the unaffected adults, its
presence was unequivocal. Since GM3 synthase is the key enzyme involving the initial
stages of ganglioside biosynthesis, GSD would theoretically result in a complete absence of
GM3 and all downstream biosynthetic derivatives in these patients [14-16]. Given that a
fair amount of GM3 was detected in the most affected patients, the question raised from the
result is where the GM3 comes from. It is possible that the detected GM3 amount may be
ingested from milk or food or generated from some unidentified ganglioside biosynthetic
pathways in humans. Apparently the origin of the GM3 in the plasma from GSD patients
remains elusive and is currently under investigation in our laboratory.

3.4 Conclusion
This study detailed the development and validation of a sensitive LC-MS/MS
method for the determination of monosialogangliosides GM1, GM2, and GM3 in human
plasma via PAEA&DMTMM-based chemical derivatization by using 2D3-GM1, 2D3-GM2,
and 2D3-GM3 as ISs. In brief, the standards and ISs were rapidly extracted from plasma
using protein precipitation, cleaned up through liquid-liquid extraction, and derivatized
under optimized conditions prior to LC-MS/MS analysis. This method employed the UPLC
system in gradient elution for chromatographic separation and Multiple Reaction
Monitoring (MRM) for mass spectrometric detection, which has been successfully applied
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to the measurement of ganglioside levels in plasma samples from GSD patients, carriers,
and normal human subjects. Regarding its high specificity, sensitivity, and throughput, this
method could be applicable for therapeutic evaluation and clinical diagnosis of other
ganglioside-related neurodegenerative disorders in the near future.
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Table 13 Determination of monosialoganglioside levels in plasma samples from
different specimens
Subject

Total

GM1
Mean±SD
(ng/mL)
(1.35±0.39)×103
(7.12±2.4)×102
(9.81±3.9)×102

GM2
Mean±SD
(ng/mL)
(4.71±1.8)×102
(2.38±1.0)×102
NM

GM3
Mean±SD
(ng/mL)
(9.93±2.9)×103
(6.23±1.9)×103
(1.13±0.33)×102

Normal Subject
31
GSD Carrier
12
GSD Patient
14
Note:
1. NM-Not Measurable
2. Plasma levels of GM2&GM3 below LLOQ were determined by using 20 uL plasma
sample in conjunction with 10 uL calibrator as described in Section 2.2.4, Plasma
Sample Preparation.
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3.5 Future Direction
In this study, we have developed a novel chemical derivatization-based
UPLC/MS/MS method for quantification of monosialogangliosides in human plasma with
superior sensitivity and specificity. Upon the introduction of DMTMM & PAEA
derivatization method, virtually their first application in quantitative analysis, we have
successfully enhanced the MS sensitivities of monosialogangliosides by 15~20 times
compared to other reported methods [12,17], which serves as a very significant
breakthrough in the field of ganglioside analysis on LC-ESI-MS. More importantly, by
taking advantages from significantly increased sensitivities from monosialogangliosides
upon derivatized, we have, in fact the first time, tentatively found the presence of
endogenous GM3 in the plasma circulation of patient with GSD and promisingly confirmed
this exciting finding by repetitively analyzing plasma samples from many different GSD
patients, suggesting that this finding might be acting as a milestone or even foundation for
future studies related to GSD. Furthermore, with the support from full validation data under
FDA guideline for bioanalytical method development, this standardized method will be
quite versatile in fulfilling diverse demands from clinical laboratory and answering
questions that remain elusive for other ganglioside-related clinical diseases in terms of its
high sensitivity, specificity, and throughput.
However, there are still a few aspects for further improvement. Firstly,
considering the PAEA-ganglioside derivatives are preferably analyzed in ESI positive
under acid conditions, whereas disialo- and trisialogangliosides are more easily ionized in
ESI negative under basic conditions, making them practically incompatible with each other
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for the single-run-analysis. One possible means to circumvent this problem to chemically
convert mono-, di-, and trisialogangliosides into their corresponding PAEA derivatives at
comparable degree through a one-pot reaction. Unfortunately, due to the bulky size of the
pyramiding ring from PAEA, spatial hindrance chemically prevents the DMTMM
intermediate of both disialo-and trisialogangliosides from undergoing the dual coupling
with PAEA and makes the formation of di-PAEA- and tri-PAEA-ganglioside derivative
extremely unfavorable by this reaction as shown by our previous study, which generates a
great bottleneck for their MS analysis. After numerous trial-and-error studies, we have
discovered that the one-pot derivatization of mono-, di-, and trisialogangliosides becomes
feasible only when a structural analog of PAEA with diminished chemical size is used in
place of PAEA for the amidation reaction, suggesting improved reactivity of
multisialogangliosides is directly associated with reduced intensity of spatial hindrance
their DMTMM intermediates experience in the course of the coupling reaction (data not
shown).
In addition, based on chemical structures of different gangliosides,
alpha-carboxylic acid group at the sialic acid residue Neu5Ac of carbohydrate moiety
might have been the only possible target that can undergo chemical derivatization.
Unfortunately, since carboxylic acid groups are ubiquitously presented on numerous
compounds existing in the biological fluid, the chemical selectivity of reactions targeting
carboxylic acid group has become a very critical challenge for their practical application. In
this study, although the solvent system of the reaction has been optimized to reduce the
amount of potential interferences introduced by the plasma matrix and excess quantity of
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DMTMM&PAEA reagents has been used to maximize the reaction yield, decent degree of
reduction on the reaction yield has still been observed following in-matrix derivatization.
This matrix intervention problem becomes even more significant when plasma quantity is
scaled up for larger-scale analysis. In addition, as the quantities of derivatizing chemicals
are enlarged in line with the increased matrix intervention from up-scaled plasma sample,
certain degree of column overload has been observed to cause peak widening and tailing
from the experiments. As a result, liquid-liquid extraction method might not be a suitable
option in handling plasma samples with increased scale. Thus, extraction methods with
greater robustness, such as solid phase extraction, would be needed to process and clean up
larger scale plasma sample for the analysis in terms of the elimination of matrix
interferences.
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CHAPTER Ⅳ

CLINICAL STUDIES ON PATIENTS WITH GANGLIOSIDE GM3 SYNTHASE
DEFICIENCY

4.1 Introduction to Ganglioside GM3 Synthase Deficiency and G500 Therapy
GM3 synthase is essentially a ubiquitously expressed protein that is particularly
abundant in the central nervous system of vertebrates. The primary function of this protein is
to catalyze the enzymatic transferring of sialic acid residue Neu5Ac onto the substrate,
lactosylceramide, through the α-2, 3-glycosdic linkage. In human, it is a protein encoded by
SIAT9/ST3Gal5 gene which is located at chromosome 2p11.2 and composed by 14 exons that
encode 419 amino acid residues. This protein is characterized by the presence of three very
distinguished regions on its primary structure, a single transmembrane region spanning across
the mammalian cell membrane, a long sialyl motif, and a short sialyl motif, all of which are
found to be essential in order for the protein to exert its normal enzymatic function.
Ganglioside GM3 Synthase Deficiency (GSD) is an autosomal recessive disorder
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prevalently identified in the Amish population around the U.S. The primary pathogenesis of
this unique disorder is etiologically attributed to the inborn-onset metabolic disruption on the
biosynthetic pathway of gangliosides associated with a homozygous loss-of-function
mutation occurred on one of the vital enzymes, GM3 synthase, for the de-novo biosynthesis
of a- and b-series gangliosides. Based on the nature of autosomal recessive inherited disorder,
a heterozygous carrier of this mutation in general does not have any clinical manifestation as
an unaffected individual differing only in the level of GM3 within the circulations which
appears to be slightly (20~30%) lower than the unaffected individual. In contrast to
heterozygous carrier, the homozygous patient of this mutation suffers severe clinical disease
as the endogenous biosynthetic GM3 as well as the GM3-derived downstream more complex
ganglioside a- and b-series have been completely depleted from their physiological systems
by the genetic defect (Fig.18) [1-4].
The homozygous loss-of-function mutation accounted for this unique disorder
has been discovered by Simpson et al. to be a single base substitution pertaining to position
694 from cytidine to thymine causing a DNA codon shifting from “CGA” arginine codon to
“TGA” stop codon. Furthermore, the mutation has been mapped on the exon 8 of GM3
synthase genome, which is located right between the long and short sialyl motifs, leading to
the unsuccessful translation of short sialyl motif and thus the truncated primary sequence in
the mutant protein [5].
A number of studies have documented substantial evidence to demonstrate that
both long and short sialyl motifs possess a highly conserved cysteine residue to generate an
inter-motif disulfide linkage that has been found to be essential for the enzyme to preserve its
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catalytic capability. As the formation of inter-motif disulfide bond was intentionally disrupted
by substituting the invariant cysteine residue to other amino acid residues with site-direct
mutagenesis, the ability of the enzyme to transfer and attach sialic acid residue Neu5Ac onto
the substrate became completely abolished, which sheds a new light not only on elucidating
the essential role of that cysteine residue in preserving the integrity of the whole enzymatic
machinery to allow it to perform its regular catalytic duty, but also on facilitating our
understanding on the development of

disease-related symptoms in terms of the disease

etiology [6].
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Fig. 18 Genotyping results from unaffected adult, GSD carrier, and GSD patient [5].
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As gangliosides are glycosphingolipids playing crucial roles for the development
and maturation of central nervous system, the lack of gangliosides in human is extremely
devastating. For children affected by GSD, they would typically develop symptoms like
severe irritability, failure to thrive, profound developmental delay, and retractable seizure
before 6 months of age. By early childhood, the majority of affected patients will start having
cortical blindness, choreoathetosis, flaccid weakness, seizure, profound physical and mental
retardation, and become completely caregiver dependent. For years, due to the practical
limitations in adequately in-vivo modeling this neurological disorder, particularly in mice, as
mice might have a completely different ganglioside metabolic pathway from human, the
GM3 synthase knockout mice have been discovered to have essentially normal phenotypes
[7]. So, the effective treatment on this devastating condition remains highly undeveloped and
the progress on its discovery has been significantly slowed.
However, we have always believed that this is a very treatable neurological
condition from the time we identified it as we noticed that the affected children appear to be
fairly normal for approximately eight weeks after their birth, which clues us to speculate that
the affected children might have acquired sufficient amount of gangliosides from maternal
circulation before their birth to make the symptoms remain undeveloped during the early age
after birth and then gradually develop related symptoms after the endogenous gangliosides
have eventually been depleted. Based on this rationale, it becomes rather plausible that if we
can replace the endogenous gangliosides in deficient caused by this genetic defect in those
affected kids with continuous supplement of exogenous gangliosides from handful sources,
we might be able to correct their pathological stigmas and partially or restore their normal
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ganglioside biosynthetic pathway, which might eventually lead to a potential cure.
So, in the past few years, we have been searching extensively for the available
sources of supplemental gangliosides that are suitable and affordable for our intended clinical
trial. Initially, the animal tissues with relatively more abundant ganglioside content appeared
to be the most enriched and accessible natural source we could find for the study. Therefore,
three affected newborns were continuously given with a pork brain formula once they were
diagnosed with DNA mutation analysis soon after birth. This formula essentially provided
approximately 10 mg GM3 per day, with incremental amounts given along with their weight
gain. Incredibly, all infants being treated showed no early signs or symptoms of the disease
except hypotonia when they were fed on the pork brain formula, although the effects seemed
to be not as much dramatic as the similar therapy was conducted on the older children.
Unfortunately, all young children involved in the study started to develop an allergic reaction
against the pork brain formula by 9 months of age, thus this pork brain formula-based therapy
had to be discontinued on those affected kids from that point due to the complexity of brain
tissue matrix.
In the course of searching for new supplements, we identified a
highly-concentrated and appropriately formulated dairy ganglioside product, called G500,
manufactured by Fonterra in New Zealand. This G500 product is consisted of high levels of
GM3 and GD3 purified from natural sources, which has been formulated and commercialized
into a form of integral infant formula to make it suitable for direct oral administration on
daily basis with minimal restrictions. This formula has been successfully used as a nutritional
supplement in normal infants, which showed almost no signs of triggering immunological
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responses on studied infants at given dosage in the previous study [8]. With the development
of this newer generation of GM3&GD3-enriched infant formula, the continuous
supplementation of highly-pure and -concentrated gangliosides on those affected kids has
been made practical and feasible for treating this neurological disorder from the long term
perspective. Furthermore, by developing a collaborative partnership with this company, we
have been able to obtain sufficient amount of G500 product at no financial cost and fulfill the
large-scale need on this G500 product from this project for the subsequent clinical study.
Based on the promising preliminary results we have observed in the younger
children fed with pig brain formula, with continuous oral G500 supplementation on daily
basis, we first expect that the orally administered gangliosides from G500 may be adequately
absorbed and taken up into the circulation of affected patients, and utilized by their metabolic
pathway. In addition, the gangliosides provided by G500 are also expected to be delivered
across the blood-brain barrier, used by the brain of affected patients, and compensate for
metabolically deficient gangliosides in their physiological system. Finally, we hypothesize
that if the absorption and utilization of administered GM3 is a reversible pathological process,
some of the manifestations and symptoms associated with this neurological disorder might
get partially or even completely relieved by introducing adequate amounts of GM3 into their
body, particularly into the CNS, which may potentially lead to a normal life in these children
when the exogenous GM3 in adequate quantity was given before they started to develop the
related symptoms.
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4.2 Materials and Methods

4.2.1 Overall Approaches
The study design is fairly straightforward. We orally administered an adequate
amount of GM3 and GD3 gangliosides from G500 to the children with GM3 synthase
deficiency and assessed them clinically, and monitored them biochemically, particularly
focusing on bioavailability and metabolism of gangliosides, and the gangliosides’ therapeutic
effects on the intellectual disability in this condition. Since there is no endogenous
ganglioside synthesized in these patients, the study design is overly simplified in many ways.
For instance, if a detectable level of gangliosides is found in the patients’ plasma and
cerebrospinal fluid, our main hypotheses, that the orally administered gangliosides may be
adequately absorbed, taken up into the circulation, and cross the blood-brain barrier, are
confirmed. Further studies will be focusing on clinical assessments of these patients to
determine if the orally delivered gangliosides are therapeutic.

4.2.2 Quantitative Analysis on Gangliosides by LC/MS/MS
As our study is designed to determine the bioavailability and metabolism of
administered gangliosides provided by G500 in the affected patients, we are in an urgent need
to have a reliable and sensitive analytical assay on hand in order to periodically monitor and
quantitative determine the levels of administered gangliosides to be absorbed by the
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physiological circulations of studied patients. As a result, the established UPLC/MS/MS
method from chapter 3 will be used in combination with the chemical derivatization protocol
as the primary means for implementing the intended study on collected plasma samples.
In addition, as an alternative means to confirm the positive existence of GSD
disease on newborns screened and diagnosed by DNA mutation analysis, the UPLC/MS/MS
method described in chapter 2 will be serving as the secondary confirmatory technique to
rapidly assure the positive existence of targeted mutation by quantitatively looking at the
levels of endogenous GM2, GM3, GD2, and GD3 in plasma samples collected from
diagnosed patients prior to embarking on the G500 therapy.

4.2.3 Subjects of the Study
5 patients with GM3 synthase deficiency aged from birth to 26 years old were
recruited into this study and divided into two separate groups, control (n=2) and treated (n=3)
group. We plan to include as many younger patients as possible, particularly the patients
under 2 years old, as the shorter time period of exposure to this condition in the younger
patients might cause less brain damage, thus may lead to more dramatic and positive clinical
outcomes. Since contraception is against the Amish religious belief, we expect more
newborns with GM3 synthase deficiency will be coming in into these affected families, who
are going to be receiving an immediate and continuous treatment with G500 and thus
hopefully preventing the disease progress to a level at which the normal life can be brought
back once again in these new patients.
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4.2.4 Assessments
For this study, each patient is expected to receive oral ganglioside administration
for at least 12 months. Formal clinical evaluations and ganglioside measurements are
performed periodically before and during the study. The comprehensive clinical evaluations
performed include: 1) a comprehensive examination with a list of clinical parameters for each
patient by the PI and a pediatric neurologist (the pediatric neurologist will be single-blinded
as the participation information is not available to him); 2) developmental assessments,
including Battelle Developmental Inventory (2nd edition) by the developmental psychologist.

4.2.5 Dosage and Ganglioside Monitoring
The amount of the gangliosides to be administrated remains to be determined.
We estimate that 120 mg dietary ganglioside may be needed to have 2.4 mg (2%) reaching to
the brain. This amount can be delivered through 10 ml of Ganglioside 500 (G500), which
contain 50 mg GM3, 60 mg GD3 and trace amounts of other gangliosides. We expect that the
needs for gangliosides might be bigger at the start as the patients are in complete depletion
status for GM3 and its downstream derivatives. We will closely monitor the plasma
ganglioside level and increase the dosage as needed until the plasma GM3 level becomes
reasonably stable and close to the level of the low range of normal heterozygous controls.
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4.2.6 Data Analysis
Since there is no endogenous ganglioside synthesized in these patients, the data
analysis is fairly easy and straightforward. In comparison to the levels of gangliosides in
patients’ plasma and cerebrospinal fluid at the pre-dosed stage, if detectable or increased
levels of gangliosides are found in their biological circulations after being dosed with G500,
our hypotheses are confirmed. Further data analysis will focus on the comparison of clinical
assessments of these patients before and during the study to determine if the orally delivered
gangliosides are therapeutic.

4.3 Results

4.3.1 Assessment on Physical Development
Owing to the infantile-onset trait of GSD on patients affected by the homozygous
mutation, they in general begin to develop symptoms like severe irritability, failure to thrive,
profound developmental delay, and retractable seizure before 6 months of age and more
deteriorating symptoms like cortical blindness, choreoathetosis, flaccid weakness, seizure,
and profound physical and mental retardation by early childhood. So, the inborn-onset
symptoms associated with retarded and dysfunctional development on a variety of physical
parameters, such as body weight, body length, and head circumference, could not only act as
a direct and straightforward indicator for the severity of the disease progression on affected
children, but also able to serve as a characteristic marker for the early-on evaluation of
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delivery strategy as well as therapeutic effectiveness of G500 formula to the administered
patients during the ongoing clinical trial.
From the standpoint of evaluating the progression of disease severity in terms of
the degree of improvements on the physical development, the virtual values of a number of
physical parameters, including body weight, body length, and head circumference, have been
acquired in 6-month window along the ages of affected children to obtain the growth trend
and tendency regarding their physical development in comparison with the unaffected
children. As shown in Fig.19, compared to the unaffected kids, the typical physical
development of patients with GSD initially appears to be fairly normal in the first few weeks
after birth, starts to develop moderate delaying symptoms in next a couple of months, and
becomes progressively severe in terms of retardation associated with their increasing age,
which consistently matches the expected clinical outcome of GSD with age-dependent and
stage-specific severity as described previously.
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Fig.19 The disease progression in relation to the patient age
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For the purpose of evaluating the delivery strategy as well as the therapeutic
effectiveness of the G500 formula, the actual values of physical parameters, including body
weight, body length, and head circumference, have also been acquired on 3-month basis from
affected children in two separate groups, control and treated group, along their ages to
establish the pattern of overall physical development compared to unaffected kids in response
to the G500 therapy. As illustrated by Fig.20, the individual from control group (A) with no
access to G500 treatment exhibited significant deviations on the growth patterns from the
normal growth curves in all studied aspects, especially for growths after 6-month post-birth,
which can be similarly predicted from we have seen previously from other untreated patients.
However, based on the growth curves we have obtained from individuals (B&C) in
G500-dosed group, compared to the control group without receiving the G500 treatment, they
showed approximately 20~30% improvements on their physical developments and being
more mathematically correlated towards the growth pattern of normal individuals regarding
almost every single aspect in response to G500 therapy.
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A
C
B

Fig.20 Growth charts for individual patients
Results of physical examination for (A) patient with GSD; (B) patient with GSD on G500; (C)
patient with GSD on G500, and the arrow bars are indications of specific time points at which
the therapy was initially started.
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4.3.2 LC/MS/MS Analysis
Due to the ease of sample handling and collection, we have been continuously
analyzing plasma samples collected from different patients at various time points to monitor
the possible changes on ganglioside levels within the blood circulation of GSD patients
before/after the dosage of G500. As we previously speculated, if the administered GM3 and
GD3 from G500 indeed gets absorbed and utilized by the physiological system of patient to
reactivate the compromised biosynthetic pathway of downstream GM3-related derivatives,
the blood system would be the primary circulation that those absorbed gangliosides rely upon
to get spread out and delivered across the entire physiological system of the patient.
Therefore, the levels of gangliosides in the blood circulation following the G500 treatment
are expected to be continuously increased as the therapy goes on and on, which is also
consider as another important indicator of the successful administration and absorption of
G500-derived gangliosides during the clinical study.
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Fig.21 Levels of circulating monosialogangliosides in the plasma samples of GSD
patients determined by LC/MS/MS
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Practically, the analysis on plasma samples collected from patients based on a
regular 3/4-month interval has been carried out by employing the LC/MS/MS method
established in chapter 3, and a portion of the quantification results have been shown
individually in Fig.21. As can be seen from Fig.21, the patients currently undergoing
treatment generally show irregularly fluctuated pattern on the level of circulating GM3 from
80~200 ng/ml in their plasma samples in response to the progression of G500 therapy, while
the level of circulating GM2 remained consistently undetectable throughout the entire study,
which is contradicted against our hypothesis that as the changes on circulating GM3 level in
plasma turned out to be insignificant in comparison with the pre-dosed plasma level and
inconsistent with what has been expected from longterm continuous exposure of orally
administered G500 under normal physiological conditions, possibly accounting for the
absence of circulating GM2 in the patient’s plasma sample with insufficient synthetic
precursor, GM3.
Moreover, regarding the circulating GM1 whose level represents the
combination of total concentration from two predominant co-existing subspecies, GM1a and
GM1b, the concentration values presented here on GM1 are relatively less informative than
GM2 and GM3 levels for this particular study as GM1a itself belongs to the family of
GM3-derived downstream derivative, whereas endogenous GM1b is mainly synthesized by a
different precursor through a GM3-independent pathway. Based on the disease etiology as
well as the biosynthetic pathways they are involved, GM1a is expected to undergo premature
biosynthetic termination and possess consistent behavior with circulating GM2 to remain
completely absent from patient plasma samples during the analysis. However, the
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biosynthesis of GM1b is expected to be highly up-regulated in order to relieve the
accumulation of lactosylceramide in the body by fluxing the accumulated lactosylceramide
through the pathway.

4.3.3 Assessment on Intelligential Development
Based on the disease pathology described by previous studies [1-4], one of the
typical symptoms closely associated with the progression of GSD is the profound mental
development retardation, a common and characteristic clinical manifestation to the majority
of neurodegenerative disorders affecting the maturation of central nervous system (CNS),
which is a critical step in maintaining the development of intelligence and brain functions at
regular pace. In the absence of endogenous GM3 as well as its downstream complex
metabolites, all of which are indispensable molecular valves ascertaining the CNS is
appropriately matured and regulated, development of normal intelligence and brain functions
have been demonstrated to be severely compromised under this particular physiological
condition. From this regard, the extent to which the intelligential development has been
virtually improved before/after G500 therapy could certainly be used as one of the primary
clinical indicators to establish the logical correlation between the therapeutic effectiveness of
administered G500 and progression of GSD.
The results of intelligential development assessment from two affected patients
have been summarized and shown in Fig.22. In Fig.22, parameters related to intelligential
development have been determined in parallel studies between the G500-treated and
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untreated patients before/after the intervention at comparable timelines, and the measured
values have been normalized to standard levels to evaluate the potential impact of
administered G500 in terms of clinically improving their intelligential activities along the
therapeutic intervention. As illustrated by Fig 4.5, in comparison with untreated patient who
in general possesses minimally developed or even highly undeveloped physical behaviors
pertaining to his/her intelligential development at the age of 24-month, pretreated patient
overall displays more progressive trends of development on intelligence except for fine motor
at the age of 26-month. However, as the pretreated patient embarking on the therapeutic
intervention, significant degree of behavioral improvements have been observed in aspects
like self care and self conception, whereas minor improved or even reduced levels of
intelligential activities have been observed in other studied criteria on treated patient
compared to the untreated one at the age of 42- and 41-month, respectively.
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B

Fig.22 Comparison on intelligential development assessment between one control and
one treated patients before(A)/after(B) the therapeutic intervention
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4.4 Discussion

4.4.1 Assessment on Physical Development
Based on Fig.19, one very interesting observation to note is that children affected
by GSD generally have comparably normal clinical behavior and developmental trend at the
time of birth, which could be primarily ascribed to their continuous absorption of exogenous
a- and b-gangliosides via maternal circulation during embryogenesis due to their incapability
of endogenously synthesizing a- and b-gangliosides on their own, confirming part of our
hypothesis that the homozygous affected babies receive the major source of supplemental
gangliosides from their heterozygous mothers for being able to maintain the regular pace of
their development at the pre-natal stage. However, as the maternal provision on supplemental
gangliosides has been physically terminated from them after birth, their circulating a- and
b-gangliosides start to undergo gradual depletion from their bodies, which is usually
accompanied by the gradual development of typical early signs of neurodegenerative
disorders, particularly seriously delayed physical development. Moreover, the developmental
retardation directly corresponding to the disease progression becomes increasingly severe as
their demand in obtaining molecules of GM3 and its downstream derivatives gets
progressively urgent with increasing age, which is also complied with our previous
predictions on the further development of other complex symptoms associated with this
clinical condition, suggesting that the severity of physically developmental retardation is
essentially a good clinical marker for the evaluation of age-dependent and stage-specific
progression of this unique syndrome.
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In Fig.20 (A), a typical progressive developmental stagnation pattern following
age-dependent manner has also been described in terms of three variables, body weight, body
length, and head circumference, from a 3-year old boy affected by GSD. As shown by the
growth charts from Fig.20 (A), the physical growth of this boy appears to be fairly normal in
the first 6 months after birth, falls out from the reference ranges of normal growth in
following months, and continues to stay degenerately deviated from the normal curves for the
rest of the studied period, which is consistent with the result from Fig.19.
However, in the presence of G500 therapy, another 3-year old boy affected by
GSD who starts off the initial G500 intervention at the age of 12-month, as described in
Fig.20 (B), has undergone significant improvements on his physical development to boost his
falling growth curves back into the reference ranges in terms of body weight and head
circumference after the existing gangliosides received from maternal circulation have been
thoroughly depleted from his body, suggesting that those exogenous gangliosides provided by
G500 formula have somehow been absorbed and utilized by his physiological system to
replace the missing gangliosides from the metabolic pathways, reactivate the metabolism and
biosynthesis of a- and b-ganglioside series, and thus facilitate his physical development from
the early stage, which closely matches a portion of our hypothesis that the orally administered
gangliosides from G500 could be absorbed by the patient’s physiological circulations and
utilized by the biosynthetic and metabolic pathways to make more complex downstream
derivatives.
Likewise, based on the growth curves from another 18-month old girl affected by
GSD, who embarks on the G500 intervention at the age of 6-month, as described in Fig.20
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(C), she has displayed a full spectrum of significantly improved growth curves well above the
minimal cutoff of the reference ranges. More importantly, compared to the previous
36-month old boy, she has showed even more significant improvements on her physical
development in all studied aspects when the intervention was initiated 6-month earlier,
suggesting that affected children with younger age might receive less serious damage to their
body from the metabolic disruption and depletion as they suffer shorter exposure to
ganglioside deficiency in terms of timeframe and thus are more sensitive and responsive to
the G500 intervention than the older ones. Namely, the earlier those affected children begin to
receive the G500 intervention, the better chance they stand of possibly getting more
effectively treated by the G500 therapy, confirming some of our hypothesis on treatment
implementing strategy.

4.4.2 LC/MS/MS Analysis
In Fig.21, quantitative results from three patients with GSD receiving G500
therapy have been selected to represent the entire treated group and demonstrate the potential
changes on monosialoganglioside levels in patient’s plasma circulation in response to the
daily

G500

administration.

Based

on

the

plasma

concentration

levels

of

monosialogangliosides presented in Fig.21 (A), the circulating GM3 level unexpectedly
vibrates up and down along the baseline value in a very irregular pattern in response to the
G500 intervention, whereas the circulating GM2 level remains constantly undetectable during
the analysis, suggesting the possibilities of either inefficient absorption of exogenous GM3
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and GD3 from G500 by blood circulation through oral administration or the rapid
flux-through of absorbed GM3 and GD3 on the metabolic intermediates by the over-active
enzymes for the biosynthesis of complex ganglioside molecules at the terminal of the
pathway. In comparison with circulating GM2&3 levels, level of circulating GM1 seems to
be not quite indicative as this concentration value represents essentially the sum of
concentrations from two co-existing positional isomers, GM1a and GM1b, both of which are
essentially GM1 gangliosides with the sialic acid residue being placed at disparate positions
and appear to have completely opposite behaviors in the course of G500 treatment and
disease progression, leading to unpredictable consequence based on alterations on total GM1
concentration during the current study.
Likewise, based on quantification results we have observed from patients in
Fig.21 (B) & (C), the levels of GM1&2&3 have been found to possess similar quantitative
behaviors in the plasma circulation of other patients as we have seen previously, which could
be potentially used as a representation to gain the general picture on patient’s overall response
to the ongoing G500 intervention implemented through oral administration at the blood
circulation level. However, due to the possible actions of either aforementioned reasons or
even the combination of both, from this study, we failed to quantitatively observe the
outcome of major increases on the levels of metabolic intermediates along the pathway in the
blood circulation of patients dosed with G500 as we expected, which might require a more
robust analytical method that is capable of including more downstream derivative species
onto the quantification list and further identify the actual cause that is responsible for this
undesirable outcome. Unfortunately, owing to the practical limitations we have encountered
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from the analytical instrumentation as well as the methodology, the method with the ability to
simultaneously quantify a full panel of analytes of our particular interest from the metabolic
pathway is still undergoing initial methodological design on the early phase.

4.4.3 Assessment on Intelligential Development
Based on the concepts of fundamental psychology, Battelle Developmental
Inventory is defined as the measurement of developmental milestones allowing adaptations
for specific disabilities, including cognitive skills, adaptive skills, motor skills,
communication skills, and personal-social development, whereas Vineland Adaptive
Behavior Scale is described as the measurement of adaptive behaviors associated with the
ability to cope with environmental changes, including fundamental socialization skills,
communication skills, basic motor skills, and daily living adeptness. So, based on these
psychological definitions, a combination of Battelle Developmental Inventory-2 and Vineland
Adaptive Behavior Scale-2 have been selected as the primary criteria to evaluate the potential
improved level of intelligential development on G500-treated patients versus the
G500-untreated ones under this particular circumstance.
In Fig.22 (A), the baseline values of intelligence-associated psychological
behaviors have been evaluated on two studied patients prior to the commencement of G500
therapeutic intervention, and it has been revealed that the 26-month old patient displaying
more significantly aggressive pattern of intelligence-related behavioral development then the
24-month old patient in the majority of studied aspects except for fine motor whose level are
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equivalently developed in both studied subjects, implying the possibility of age-dependent
baseline shifting between studied patients on the measuring values in relation to intelligential
development, which might act as a possible influential factor affecting the data quality of
following studies.
In Fig.22 (B), with the continual administration of G500 to one of the studied
patients, in comparison with the untreated patient, the extent to which the psychological
activities associated with the intelligential development are being virtually improved have
been observed to be significant for self care and self concept, suggesting the gangliosides
absorbed by the patients’ physiological system and utilized by their metabolic pathways from
administered G500 might have been therapeutic in terms of facilitating the intelligential
developments on self-related behaviors. However, only minor/none degree of behavioral
improvements have been observed for aspects like adult interaction, expressive
communication, fine motor, attention/memory, and perception/concepts, which might be
caused by shifting on the baseline values at the pretreated stage. Surprisingly, the treated
patient has been found to possess diminished level of receptive communication development
compared to the untreated one, which is not consistent with the psychological patterns
determined by other intelligential behaviors.

4.5 Conclusion
In the present work, we proposed a therapeutic intervention strategy based on
oral administration of exogenous gangliosides to cure an inherited neurological disorder,
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Ganglioside GM3 Synthase Deficiency, and established a systematic approach to
biochemically evaluate the clinical behaviors of studied patients as well as the therapeutic
effectiveness of the proposed therapy from many different aspects. From the clinical
perspective, compared to untreated patients suffering severe physical and mental
developmental stagnation, treated patients displayed significantly improved physical
development and moderately improved psychological behavior as the treatment progresses,
implying the ultimate uptake and utilization of the administered gangliosides by their
physiological systems to replace the missing gangliosides from their metabolic pathways.
From the analytical perspective, the plasma levels of circulating monosialogangliosides
determined by LC/MS/MS from treated patients showed inconsistent patterns of fluctuation
compared to baseline values determined from the pre-treated stage, suggesting the possibility
of rapid metabolism of exogenous gangliosides might have undergone to downstream
derivatives following their physiological absorption.
By principle, plasma level of free GM3 acts as a direct reflection on the
abundance of GM3 being integrated onto the cell membrane lipid bilayer as a physiological
equilibrium must be existing between the unbound GM3 presenting in the blood circulation
and bound GM3 incorporated to the cell membrane. In the complete absence of endogenous
unbound GM3 in patient blood circulation in response to enzymatic dysfunction on GM3
synthase, the level of bound GM3 being integrated into the glycolipid-enriched microdomain
is expected to be equivalently absent from the cell membrane. Additionally, as GM3 serves as
a universal and indispensable synthetic precursor for the de-novo biosynthesis of a- and
b-ganglioside series, its endogenous absence usually causes the premature biosynthetic
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termination of all GM3-derived downstream metabolites, especially those more complex
gangliosides such as GD1a, GD1b, GT1a, and GT1b, all of which are fine molecular
regulators in modulating cell proliferation, differentiation, migration, and adhesion during the
maturation and maintenance of physiological and psychological systems, leading to the
substantial alternations on the composition and organization of lipid-anchoring scaffold
within the lipid raft and thus the significant disruptions on the ordinary functionalities of
glycolipid-enriched microdomain in orienting the incorporated cell surface receptor tyrosine
kinases towards the incoming ligands for transmitting the extracellular biological signaling
into the cytoplasmic machinery. Based on previous studies, although it has been revealed that
increased GM3 level in general up-regulates the inhibitory effects on the dimerization and
autophosphorylation of the majority of receptor tyrosine kinases, whereas the increased level
of its downstream derivatives, including GD1a, GD1b, GT1a, and GT1b, has also been found
to be able to effectively activate those receptors by inducing the dimerization of the
extracellular ligand-binding domain and the subsequent autophosphorylation of the
cytoplasmic tyrosine kinase domain at low concentration or complete absence of specific
ligands, suggesting distinctive regulatory roles of various ganglioside species. As a result, the
overall impact of the metabolic disruptions by genetic defects, as demonstrated in the case of
GSD patients, on balancing act between the molecular interactions of GM3 and its
downstream more complex metabolites with individual receptor tyrosine kinases seems to be
the primary driving force accounted for the pathogenesis of GSD as well as the eventual
development of severe symptoms associated with the disease, which could be better
illustrated by analyzing results obtained from clinical studies in conjunction with discoveries
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reported by other studies as following.
Recently, previous study has demonstrated that GD1a, one of the major
downstream metabolites of GM3 from the biosynthetic pathway of a-series ganglioside that
are expected to present in the blood circulation of patients undergoing G500 treatment, is
capable of stimulating the proliferation of normal human dermal fibroblasts by promoting the
EGFR dimerization through a ligand-independent mechanism and hence enhancing the
autophosphorylation of the cytoplasmic tyrosine kinase domain of EGFR, leading to the
subsequent activation of Ras and Raf, which in turn causes the EGFR-mediated activation of
mitogen-activated protein kinase (MAPK) pathway [9]. Moreover, alternative study has also
discovered that GD1a facilitates the differentiation of human mesenchymal stem cells to
osteoblasts primarily by stimulating the autophosphorylation of cytoplasmic tyrosine kinase
domains from extracellular signal-regulated kinases (ERK), mitogen-activated protein kinase
(MAPK), and epidermal growth factor receptor (EGFR). In the presence of decreased level of
GD1a through knockdown of ST3GalⅡ, the enzyme that catalyzes the synthesis of GD1a
from GM1, by shRNA transfection, inhibitory effects caused by reduced phosphorylation of
ERK, MAPK, and EGFR has been observed during the differentiation [10], implying one of
the potential molecular mechanisms by which the physical developments of treated patients
are clinically improved by acquiring certain amounts of circulating GD1a through the
metabolism of absorbed exogenous GM3 and stimulating the activity of EGFR and its
downstream signaling cascades upon its interaction with GD1a.
In addition, it has been revealed that the over-expression of gangliosides,
especially GD1b and GT1b, significantly enhances the proliferation of a rat
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pheochromocytoma cell line (PC12) by transfecting the cell line with ganglioside GD3
synthase gene. The increased levels of GD1b and GT1b, both of which are major downstream
metabolites of GM3 from the biosynthetic pathway of b-series gangliosides that are expected
to present in the blood circulations of treated patients, stimulate the proliferative event by
continuously phosphorylating the tropomyosin receptor kinase A (TrkA) and constitutively
inducing a conformational change of TrkA to form a active dimer, leading to elevated
activation of the downstream ERK1/2 and PI3K/Akt pathways even in the absence of nerve
growth factor (NGF) [11], suggesting an alternative molecular mechanism by which the
significant improvements on physical development of treated patients in comparison with
control patients are accomplished partially through the cell proliferation stimulated by
triggering an continual dimerization of Trkt and activation of ERK1/2 and PI3K/Akt
pathways with elevated levels of GD1b and GT1b.
Furthermore, mounting evidence has also illustrated that the hepatocyte growth
factor receptor c-Met displayed a ganglioside-dependent manner of activation in breast
cancer cells by expressing the GD3 synthase in MDA-MB-231 breast cancer cells to induce
the cell surface accumulation of b- and c-series gangliosides, including GD3, GD2, and GT3,
all of which are practically accessible to the patients receiving ongoing oral administration of
G500. Among these complex gangliosides, GD2 was found to be extensively implicated in
the activation of c-Met as well as the subsequent activation of MEK/ERK and PI3K/Akt
signaling pathways, leading to enhanced cell migration and proliferation, which is further
confirmed with the competition assays by competitively blocking the oligosaccharide moiety
of GD2 from interacting with the c-Met using anti-GD2 mAb and thus inhibiting the
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phosphorylation of c-Met. Comprehensively, markedly reduced levels of GD2 biosynthesis
and c-Met phosphorylation and the reverse proliferative phenotypes were observed as the
GD2 synthase gene was silenced by siRNA transfection [12-14], indicating the potential
regulatory role of GD2 in facilitating the physical and mental development of treated patients.
Finally, it has been evident that ganglioside enrichment in human umbilical vein
vascular endothelial cells (HUVEC) can sensitize the vascular endothelial growth factor
receptor (VEGFR) by inducing the VEGFR dimerization and auto phosphorylation at
sub-threshold level of VEGF, causing the subsequent activation of VEGFR/PKC/MAPK and
VEGFR/PI3K/MAPK pathways, which in turn leads to the markedly potentiated cell
proliferation and migration [15]. In parallel studies, pre-incubation of HUVEC with
exogenous GD1a prior to the addition of VEGF has also been found to substantially
up-regulate the VEGF-induced cell proliferation and migration [16], shedding a new light on
elucidating the underlying mechanism by which the clinical symptoms of GSD on treated
patients are being gradually relieved in response to the G500 therapeutic intervention
strategy.
Overall, this oral administration-based therapeutic intervention strategy
demonstrates certain potentials in terms of curing this infantile-onset clinical condition,
especially for affected newborns that typically have short exposure to the premature
ganglioside biosynthetic termination and endogenous depletion. Since this is the first study to
use dairy-originated gangliosides to treat a metabolic defect and assess the bioavailability and
metabolism of orally administered gangliosides in humans, we believe that this therapeutic
strategy might serve as a breakthrough for treating this devastating condition. Moreover, as
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gangliosides’ neurotrophic and neuritogenic effects have already been demonstrated in
various neurodegenerative disorders, such as Parkinson’s disease and Alzheimer’s disease,
the therapeutic implications of this study might be much broader. Considering the
gangliosides in our study are obtained from milk and given orally, the therapy could fall into
the category of nutritional supplementation, which might dramatically accelerate its
implications in all ganglioside-related neurological conditions. Undoubtedly, this study sheds
a new light on fundamentally understanding the physiological and pathological functions of
gangliosides in human brain.

4.6 Future Direction
In this study, we implemented a clinical study in attempts to treat an inherited
metabolic disorder associated with ganglioside GM3 biosynthesis by using a therapeutic
intervention strategy based on oral administration and established a corresponding assessment
system to biochemically evaluate the clinical response of studied patients as well as the
therapeutic effectiveness of the therapy. Based on the results we collected from the clinical
trial, the treated patients in general displayed positive feedbacks in terms of relieving the
severity of the developing symptoms from the clinical standpoint, demonstrating the potential
of this therapeutic intervention strategy in treating this particular condition. However, from
the analytical standpoint, the concentration values of several major metabolic intermediates
on the pathway in the plasma circulation of studied patients showed irregular variation
around the baseline value in response to the therapy progression, signifying that minor
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quantity of administered molecules might have been obtained from the absorption event
during delivery and the rapid influx and efflux of absorbed molecules through the whole
metabolic pathway, both of which could be attributed to inefficient delivery and inconsistent
absorption pattern of administered molecule in relation to the complexity of oral
administration. As a result, the conditions of oral administration associated have to be further
optimized to improve the delivery as well as absorption efficiency and thus increase the
bioavailability of the administered molecule for being able to observe more confident,
promising, and convincing clinical outcomes from the ongoing clinical trial.
By principle, oral administration is usually well-known as the most complicated
drug delivery system with the most unpredictable outcome as the orally administered
molecule might be subject to all possible kinds of physiological modifications and
degradations associated with digest system prior to its entry into the blood circulation and
ultimate reachout to the targeted site for interaction. Based on our discussion on gangliosides’
molecular structure from the previous chapter, the only possible site available for covalent
modification on their structures is the protruding carboxylic acid group on the sialic acid
residue Neu5Ac, which might be subjected to modifications like esterification,
decarboxylation, and amidation catalyzed by various enzymes as they are traveling through
the different physiological system. Therefore, the co-administration of synthetic carboxyl
group-containing structural analog, GM4 for instance, in combination with G500 formula is
necessitated to substitute administered gangliosides from undergoing possible structural
modifications and thus preserve them to proceed into the circulations in their original
structure, enabling them to further participate into the metabolic pathway and exert their
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normal biological functions to compensate for the physiological damage caused by longterm
GM3 deficiency.
In addition, as gangliosides are featured by carbohydrate moieties made up with
monosaccharide building blocks through either α-1, 3- or α-1, 4-glycosidic linkage except for
Neu5Ac whose linkages are usually α-2, 3- or α-2, 4-glycosidic bond, stomach who has the
capability of secreting the gastric acid and reducing the PH to as low as 2 during the digestion
could potentially act as the primary organ facilitating the degradation of administered
gangliosides and breaking them down into individual monosaccharide units before they are
absorbed by the circulations due to the fact that glycosidic bonds are extremely sensitive and
fragile to hydrolysis catalyzed by high concentration of acids. Hence, in order to preserve
administered gangliosides to enter the circulations in their biological active form, the
secretion of gastric acid by the stomach has to be properly inhibited by synthetic inhibitors
specifically targeting the gastric acid secretion pathway to minimize their possible
degradation while the oral administration is undertaken. Currently, two main classes of
gastric acid secretion inhibitors have been made available to the market, histamine
H2-receptor antagonists and proton pump inhibitors, both of which are FDA approved drugs
to treat disorders associated with gastric acid secretion. Mechanistically, the histamine
H2-receptor antagonists act by reversibly blocking the action of histamine to its receptor, a
stimuli released by neighboring mucosal cells to stimulate the secretion of gastric acid in
anticipation of a meal or when the food enters the stomach, which is capable of moderately
elevating the pH value in the stomach by approximately one unit. While the proton pump
inhibitors act by inactivating the final step in acid secretion - the transportation of proton ions
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from the parietal cells to the lumen of the gastric glands, which has a more potent and longer
lasting effect on acid secretion than the histamine H2-receptor antagonists, allowing larger
amount of administered gangliosides to survive through gastric digestion and longer time
window for the subsequent absorption to take place in the intestine. Expectedly, with the
co-administered proton pump inhibitors to reduce the secretion of gastric acid, more
exogenous gangliosides from G500 would get thoroughly preserved through the gastric
digestion for later absorption, and thus their bioavailability in the blood circulation would be
increased significantly.
Lastly, since gangliosides are predominantly localized at the outer leaflet of cell
plasma membrane in a special configuration where the hydrophobic ceramide portion is
embedded inward into the plasma membrane for stable anchoring and the hydrophilic
carbohydrate moiety is protruding outward into the extracellular matrix for accessible
interaction, their carbohydrate moieties are usually conferred with pretty high degree of
protein-binding affinity via non-covalent interactions like hydrogen bonding and electrostatic
interaction, which possibly prohibits them from being taken up by the tissues or cells around
the circulations as the huge size of ganglioside-protein complex makes it stand little chance
of penetrating through and being settled down onto the cell membrane. More importantly, the
dissociation of this ganglioside-protein complex could be an unfavorable kinetic process,
which impedes the release of gangliosides into their free molecular forms and requires the
application of a carrier vehicle to create an isolated protein-free environment to physically
prevent the interaction from happening between gangliosides and proteins. Therefore, the
enriched gangliosides purified from cow or bovine milk are ought to be formulated into a
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protein-free lyophilized powder and encapsulated into carrier vehicle along with proton pump
inhibitors as well as carboxyl group-containing structural analogs for administration to
increase the efficiency of preservation and reduce the occurrence of undesirable
bindings/interactions with other proteins during the absorption.
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